

**A STUDY ON THE ASSOCIATION BETWEEN HbA1C AND
VITAMIN D LEVELS IN TYPE 2 DIABETES MELLITUS.**

By

Dr. Kamalakar. S. Desai

Dissertation submitted to BLDE University, Bijapur



In partial fulfillment of the requirements for the degree of

MD

in

General Medicine

Under the guidance of

Dr. L.S.Patil M.D

Professor

Department of Medicine,

Shri B.M. Patil Medical College, Bijapur.

2014 – 15

**B. L. D. E. U'S
SHRI B. M. PATIL MEDICAL COLLEGE HOSPITAL &
RESEARCH CENTRE, BIJAPUR.**

DECLARATION BY THE CANDIDATE

I hereby declare that this dissertation/thesis entitled “**A STUDY ON THE ASSOCIATION BETWEEN HbA1C AND VITAMIN D LEVELS IN TYPE 2 DIABETES MELLITUS**” is a bonafide and genuine research work carried out by me under the guidance of **Dr. L. S. Patil**, M.D., Professor, Department of Medicine, Shri B.M. Patil Medical College, Bijapur

Date:

Place: Bijapur

Dr. Kamalakar S. Desai

**B. L. D. E. U'S
SHRI B. M. PATIL MEDICAL COLLEGE HOSPITAL &
RESEARCH CENTRE, BIJAPUR.**

CERTIFICATE BY THE GUIDE

This is to certify that the dissertation entitled “**A STUDY ON THE ASSOCIATION BETWEEN HbA1C AND VITAMIN D LEVELS IN TYPE 2 DIABETES MELLITUS**” is a bonafide and genuine research work carried out by **Dr. Kamalakar S Desai** in partial fulfillment of the requirement for the degree of MD in General medicine.

Place:

Date:

Dr. L. S. Patil, M.D.
Professor
Department of Medicine,
Shri B.M. Patil Medical
College, Bijapur.

**B. L. D. E. U'S
SHRI B. M. PATIL MEDICAL COLLEGE HOSPITAL &
RESEARCH CENTRE, BIJAPUR**

**ENDORSEMENT BY THE HOD, PRINCIPAL / HEAD OF THE
INSTITUTION**

This is to certify that the dissertation entitled “**A STUDY ON THE ASSOCIATION BETWEEN HbA1C AND VITAMIN D LEVELS IN TYPE 2 DIABETES MELLITUS**” is a bonafide research work done by Dr. Kamalakar S Desai under the guidance of, Dr. L.S.Patil M.D., Professor, Department of Medicine, Shri BM Patil Medical College, Bijapur.

Seal & Signature of
HOD of Medicine

Dr. M.S. MULIMANI M.D (Medicine)
BLDEU's Shri B.M. Patil
Medical College, Hospital &
research Centre, Bijapur

Date:
Place: Bijapur

Seal and signature of
the principal

DR.M.S.BIRADAR M.D. (Medicine)
BLDEU's Shri B.M. Patil
Medical College, Hospital &
Research Centre, Bijapur.

Date:
Place: Bijapur

**B. L. D. E. U'S
SHRI B. M. PATIL MEDICAL COLLEGE HOSPITAL &
RESEARCH CENTRE, BIJAPUR.**

COPYRIGHT DECLARATION BY THE CANDIDATE

I hereby declare that the BLDE University, Karnataka shall have the rights to preserve, use and disseminate this dissertation / thesis in print or electronic format for academic / research purpose.

Date:

Place: Bijapur

Dr. Kamalakar S. Desai.

ACKNOWLEDGEMENT

First and foremost, I would like to thank God for all the blessings he's given me. I would like to express my sincerest gratitude to my guide Dr. L.S. Patil MD, Professor of Medicine, under whose inspiring guidance & supervision, I am studying and continuing to learn & master the art of medicine. He has taught me how to think critically, write scientifically and present research meaningfully. I am truly grateful for his mentorship over these past few years and I am certain that he will guide me in my career path.

I would also like to express my sincere thanks to our principal Professor Dr. M.S. Biradar MD, for his kind support.

I am also grateful to my other teachers, Dr R.C.Bidri, Dr. S.N. Benteor MD, Dr. S. S. Devarmani MD, Dr. S. R. Badiger MD & Dr. M.S. Mulimani MD, Professors of Medicine.

My sincere thanks to all the staff of the Department of Biochemistry, the Department of Pathology, Shri B.M. Patil Medical College Hospital & Research Centre, Bijapur who helped me in the laboratory investigation work.

I would be failing in my duty, if I would not acknowledge my thanks to all the patients who were kind enough to help me for this study.

I would also like to thank my parents, without whose constant encouragement & moral support, my studies would have been a distant dream.

Dr. Kamalakar S. Desai

LIST OF ABBREVIATIONS USED

α	-	Alpha
β	-	Beta
μg	-	Micro gram
1,25(OH)2D3	-	1 α , 25-dihydroxyvitamin D3
ADA	-	American Diabetes Association
Akt	-	Protein kinase B
BMI	-	Body mass index
CDC	-	Center for Disease Control
CoA	-	Co-activator
CoR	-	Co-repressor
CV	-	Co-efficient of variation
DBP	-	Diastolic blood pressure
DCCT	-	Diabetes Control and Complications Trial
DM	-	Diabetes mellitus
DNA	-	Deoxyribonucleic acid
e.g.	-	For example
ESRD	-	End stage renal disease
FPG	-	Fasting plasma glucose
GAD	-	Glutamic acid decarboxylase
GDM	-	Gestational diabetes mellitus
GLUT	-	Glucose transporter
HbA1c	-	Glycated hemoglobin
HDL	-	High density lipoprotein

HLA	-	Human leukocyte antigen
HNF	-	Hepatocyte nuclear transcription factor
hrs	-	Hours
ICMR	-	Indian Council of Medical Research
IDDM	-	Insulin dependent diabetes mellitus
IDF	-	International Diabetes Federation
IFG	-	Impaired fasting glycaemia
IGF	-	Impaired fasting glucose
IGT	-	Impaired glucose tolerance
IPF	-	Insulin promoter factor
IU	-	International units
Kg	-	Kilogram
LDL	-	Low density lipoprotein
m	-	Meter
mg/dl	-	Milligram per deciliter
min	-	Minute
mm Hg	-	Millimeter of mercury
MODY	-	Maturity Onset Diabetes of Young
n	-	Total number
NIDDM	-	Non-insulin dependent diabetes mellitus
NK	-	Natural killer
nmol	-	Nano mole
nmols/L	-	Nano moles per liter
NPDR	-	Non Proliferative Diabetic Retinopathy
NSGP	-	National Glycohemoglobin Standardization Program

OGTT	-	Oral glucose tolerance test
p	-	Prevalence
POL II	-	Polymerase II
PPBS	-	Post prandial blood sugar
RNA	-	Ribonucleic acid
RR	-	Relative risk
RXR	-	Retinoic X receptor
SD	-	standard deviation
SGOT	-	Serum glutamic oxaloacetic transaminase
SGPT	-	Serum glutamic-pyruvic transaminase
STZ	-	Streptozotocin
Tc	-	Cytotoxic
TCF7L2	-	Transcription factor 7-like 2
TSH	-	Thyroid stimulating hormone
VDR	-	Vitamin D response
VDRE	-	Vitamin D response element
WHO	-	World health organization

ABSTRACT

Background and objectives

Recently, Vitamin D has sparked widespread interest in the pathogenesis and prevention of diabetes. The present study was undertaken to estimate the levels of Vitamin D in patients with Type 2 Diabetes Mellitus and to correlate levels of Vitamin D with Glycemic status of Diabetes Mellitus.

Methodology

The present one and half year cross sectional study was carried out in the Department of Medicine, BLDE University's Shri B M Patil medical college and research center , Bijapur from January 2013 to June 2014. A total of 125 patients with type 2 diabetes mellitus were studied. The estimation of Vitamin D was done using Siemens, ADVIA Centraur VitD assay, a one pass 18 minute antibody competitive immunoassay.

Results

Maximum number of cases were in the age group of 51 to 60 that is 40 patients (32%). The mean age of study population was 60.22 ± 11.65 years. Out of 125 patients, 77 (61.6%) were males and 48 patients (38.4%) were females, with a ratio of male to female of 1.60:1. In 104 patients (83.2%), the levels of Vitamin-D were below normal, in 11 patients (8.8%) the levels were insufficient and in remaining 10 patients (8%) the levels were either normal or more than normal.

Most of the patients had fasting and post prandial glucose abnormality (98.4% and 96% respectively).

Conclusion and interpretation

There was an inverse association between Vitamin D levels and HbA1c in patients with type 2 diabetes mellitus. Lower Vitamin-D levels were associated with poor glycemic control. Additionally we observed a significant correlation of Vitamin-D levels with variable factors like total cholesterol and low density lipoprotein (LDL). However, we did not find significant correlation with variable factors like age, gender, duration of diabetes, body mass index, fasting blood sugar, post prandial blood sugar, high density lipoprotein (HDL) and triglycerides.

Keywords

Diabetes mellitus; Glycaemic control; Vitamin D;

CONTENT

Sl. No	Topic	Page No
1	INTRODUCTION	1
2	AIMS AND OBJECTIVES	5
3	REVIEW OF LITERATURE	6
4	MATERIALS AND METHODS	59
5	OBSERVATIONS AND RESULTS	64
6	DISCUSSION	90
7	SUMMARY	94
8	CONCLUSION	95
9	BIBLIOGRAPHY	96
10	ANNEXURES	
	I ETHICAL CLEARANCE CERTIFICATE	109
	II CONSENT FORM	110
	III PROFORMA	113
	IV MASTER CHART	117

LIST OF TABLES

Table No	Description	Page No
1	Age distribution	65
2	Sex distribution	66
3	Duration of diabetes	67
4	Mode of treatment	68
5	Habits	69
6	Body mass index (BMI)	70
7	Fasting blood sugar (FBS)	71
8	Post prandial blood sugar (PPBS)	72
9	HbA1c levels	73
10	Fasting lipids - Total cholesterol	74
11	Fasting lipids - Low density lipoprotein (LDL)	75
12	Fasting lipids - High density lipoprotein (HDL)	76
13	Fasting lipids Triglycerides	77
14	Vitamin D levels	78
15	Correlation of Vitamin D levels with age	79
16	Correlation of Vitamin D levels with Gender	80
17	Correlation of Vitamin D levels with Duration of Diabetes	81
18	Correlation of Vitamin D levels with Body Mass Index (BMI)	82
19	Correlation of Vitamin D levels with Fasting Blood Sugar	83

20	Correlation of Vitamin D levels with Post- Prandial Blood Sugar	84
21	Correlation of Vitamin D levels with HbA1c	85
22	Correlation of Vitamin D levels with Total Cholesterol	86
23	Correlation of Vitamin D levels with Low Density Lipoprotein	87
24	Correlation of Vitamin D levels with High Density Lipoprotein	88
25	Correlation of Vitamin D levels with Triglycerides	89

LIST OF GRAPHS

Sl. No	Topic	Page No
1	Age distribution	65
2	Sex distribution	66
3	Duration of diabetes	67
4	Mode of treatment	68
5	Habits	69
6	Body mass index (BMI)	70
7	Fasting blood sugar (FBS)	71
8	Post prandial blood sugar (PPBS)	72
9	HbA1c levels	73
10	Fasting lipids - Total cholesterol	74
11	Fasting lipids - Low density lipoprotein (LDL)	75
12	Fasting lipids - High density lipoprotein (HDL)	76
13	Fasting lipids Triglycerides	77
14	Vitamin D levels	78

LIST OF FIGURES

Sl. No	Topic	Page No
1	Metabolic changes during the development of type 2 diabetes mellitus	25
2	Molecular structures of vitamin D2 (ergocalciferol) and vitamin D3 (Cholecalciferol)	44
3	Synthesis and metabolism of vitamin D	45
4	Genomic actions of 1,25-dihydroxyvitamin D3	46

INTRODUCTION

Diabetes mellitus (DM) is one of the oldest diseases known to man. It was first reported in Egyptian manuscript about 3000 years ago.¹ Diabetes can be distinguished into two types, Type 1 and Type 2. In 1936, the distinction between Type 1 and Type 2 DM was made clear.² Type 2 DM was first described as a component of metabolic syndrome in 1988.³

Type 1 Diabetes involves little or no production of insulin by the pancreas. It has often an early onset and involves medication and monitoring of blood-sugar levels. Type 2 Diabetes is characterized by defects with insulin receptors. It has often a late onset, and is associated with reduced physical activity and overweight. Medication and monitoring of blood-sugar levels are often necessary.²

Type 2 Diabetes mellitus (T2DM) is a non-autoimmune, complex, heterogeneous and polygenic metabolic disease condition in which the body fails to produce enough insulin, characterized by abnormal glucose homeostasis. Its pathogenesis appears to involve complex interactions between genetic and environmental factors.⁴ T2DM occurs when impaired insulin effectiveness (insulin resistance) is accompanied by the failure to produce sufficient insulin.⁵

It is estimated that 366 million people had DM in 2011; by 2030 this would rise to 552 million. The number of people with Type 2 DM is increasing in every country with 80% of people with DM living in low- and middle-income countries. DM caused 4.6 million deaths in 2011.⁶

The incidence of Type 2 DM varies substantially from one geographical region

to the other as a result of environmental and lifestyle risk factors.⁷ Thirty years ago, the prevalence of diabetes in India based on the Indian Council of Medical Research (ICMR) multicentric survey⁸ was around 2% in urban India and 1% in rural India. In just three decades, these prevalence rates have shot up to 12 to 16% in urban India and 3 to 8% in rural India, in adults over 20 years of age. This represents a 600 to 800% increase in prevalence rates of diabetes something which is unparalleled in any Western nation. Indeed, India is now referred as the “Diabetic Capital” of the world.

It is predicted that the prevalence of DM in adults of which T2DM is becoming prominent will increase in the next two decades and much of the increase will occur in developing countries where the majority of patients are aged between 45 and 64 years.⁹

Insulin plays a crucial role in this disease. Insulin is a hormone produced by the pancreas. This hormone regulates carbohydrates and fat metabolism. Glycated hemoglobin (HbA1c) can be measured in the blood to find out the Glycemic control.¹⁰

Further, T2DM is associated with several complications. The complications of Type 2 diabetes mellitus include retinopathy, nephropathy, and neuropathy (both peripheral and autonomic). The risk for atherosclerotic vascular disease is also increased in patients with T2DM. The risk for microvascular and neuropathic complications is related to both duration of diabetes and the severity of hyperglycemia; the increased risk for vascular disease actually antedates the onset of hyperglycemia to the degree associated with diabetes mellitus.²

Although important knowledge has been acquired on the etiology of diabetes its precise etiopathogenesis is still under discussion. Inflammatory factors, reactive oxygen species and autoimmune reactions have all strongly emerged as the major pathogenic effectors for diabetes.

Recently, Vitamin D has sparked widespread interest in the pathogenesis and prevention of diabetes. Vitamin D is a steroid which promotes the intestinal absorption and metabolism of calcium and phosphorus. There are several terms used to describe Vitamin D. Vitamin D₂ or ergocalciferol is synthesized by plants. Vitamin D₃ or cholecalciferol is synthesized in the human skin when it has been exposed to ultraviolet rays from sunlight. Food may contain Vitamin D₂ or D₃. Serum 25-hydroxyvitamin D level is the best marker of whole-body Vitamin D status. Biologically active form of Vitamin D is 1,25-dihydroxy vitamin D.¹¹

It is postulated that, Vitamin D as the major regulator for calcium homeostasis, it directly and or indirectly improves insulin exocytosis via activating calcium-dependent endopeptidases. Vitamin D also improves glucose tolerance.¹² Vitamin D could also prevent T2DM through its role as an efficient antioxidant. Additionally, the steroid hormone form of Vitamin D promotes suppressor cell activity and inhibits the generation of cytotoxic (Tc), macrophages, delayed hypersensitivity type and natural killer (NK) cells.¹³

Vitamin D also mediates several non-calcemic functions. It is a regulator of cellular proliferation, differentiation and replication, and mediator of autoimmune reactions, in a variety of organs and biological systems. The discovery of receptors for 1 α ,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃), the activated form of Vitamin D, in tissues with no direct role in calcium and bone metabolism (e.g.,

pancreatic beta-cells and cells of the immune system) has broadened our view of the physiological role of Vitamin D.^{14,15}

This novel risk factor in the development of diabetes has recently gained attention and remains unexplored.¹⁶ The study from Vacek et al. (2012) found an important role of Vitamin D in cardiovascular health and diabetes, and found that Vitamin D deficiency was related to reduced survival.¹⁷ The role of Vitamin D in T2DM is suggested by cross-sectional studies showing that low serum concentrations of 25-hydroxyvitamin D are associated with impaired glucose tolerance and diabetes.^{18,19} Vitamin D helps in insulin secretion by stimulating beta cell insulin secretion or it may facilitate the conversion of pro-insulin to insulin. Vitamin D improves insulin sensitivity and promote beta cell survival by modulating the effects of cytokines.²⁰ Therefore, Vitamin D deficiency may be implicated in pathogenesis of T2DM.

However, the role of Vitamin D in T2DM remains unexplored. So far, very few studies have explored the role of Vitamin D and type 2 diabetes mellitus in India. Hence the present study was undertaken to estimate the levels of Vitamin D in patients with T2DM and to correlate levels of Vitamin D with Glycemic status of Diabetes Mellitus.

AIMS AND OBJECTIVES

The objectives of the present study were :

- To estimate the levels of Vitamin D in patients with Type 2 Diabetes Mellitus.
- To correlate levels of Vitamin D with Glycemic status of Diabetes Mellitus.

REVIEW OF LITERATURE

Diabetes mellitus comprises a group of common metabolic disorders that share the phenotype of hyperglycemia. Several distinct types of diabetes mellitus exist and are caused by a complex interaction of genetics, environmental factors, and life style choices. Depending on the etiology of diabetes mellitus, factors contributing to hyperglycemia may include reduced insulin secretion, decreased glucose utilization, and increased glucose production.

The metabolic dysregulation associated with diabetes mellitus causes secondary pathophysiologic changes in multiple organ systems. Diabetes mellitus is the leading cause of end-stage renal disease (ESRD), non-traumatic lower extremity amputation and adult blindness. With an increasing incidence worldwide, diabetes mellitus will be a leading cause of morbidity and mortality in the future.¹

History of diabetes mellitus

Diabetes mellitus (DM) is probably one of the oldest diseases known to man. It was first reported in Egyptian manuscript about 3000 years ago.¹ In 1936, the distinction between Type 1 and Type 2 DM was made clearly. Type 2 DM was first described as a component of metabolic syndrome in 1988. Type 2 DM (formerly known as non-insulin dependent DM) is the most common form of DM characterized by hyperglycemia, insulin resistance, and relative insulin deficiency. Type 2 DM results from interaction between genetic, environmental and behavioral risk factors.²¹

Diabetes mellitus is a disease that was recognized in antiquity, but its history has been characterized by numerous cycles of discovery, neglect and rediscovery. Its history may be divided into four major periods that reflect different phases in the understanding and management of the disease. The 'ancient' period witnessed the first clinical descriptions of diabetes and complications. The 16th to 18th centuries have been termed as the 'diagnostic' period, as diabetes mellitus was then identified as a separate disease entity, while the mid to late 19th century may be regarded as the first 'experimental' period, during which the glucoregulatory role of the pancreas became clear and the biochemical disturbances of diabetes were initially characterized.¹⁴ Finally, the 20th century has seen a dramatic increase in knowledge about diabetes. The discovery of insulin in 1921-22 has had profound scientific, clinical and social consequences.

Some key developments in scientific and clinical understanding of diabetes may be summarized as follows:²²

- Polyuric states, clinically resembling diabetes mellitus were described as early as 1550 BC in the ancient Egyptian papyrus discovered by George Ebers.
- The sweet taste of diabetic urine was noted in the 5th and 6th century AD by the Indian physicians (Sushruta and Charaka) and in the 17th century by Thomas Willis. The term 'Diabetes mellitus', an allusion to the honeyed taste of urine, was first used in the late 18th century by John Rollo and others, to distinguish it from other polyuric states in which

urine was tasteless.

- In 1776, Matthew Dobson discovered that diabetic serum as well as urine contained sugar, and concluded that diabetes was a systemic condition rather than a disease of kidneys.
- Claude Bernard made numerous discoveries in the field of metabolism and diabetes during the mid to late 19th century, describing the storage of glucose in the liver as glycogen and hyperglycemia in experimental animals.
- In 1889, Oskar Minkowski and Josef Von Mering observed that total pancreatectomy produced diabetes in dogs.
- In 1893, Edovard Laguesse named the pancreatic islets after Paul Langerhans, who had described them in 1869, and suggested that they produced a glucose lowering substance. This then hypothetical hormone was named 'insulin' by Jean de Meyer in 1909, over a decade before its discovery.
- Various workers, including George Zuelzer (Germany) and Nicolas Paulesco (Romania), isolated active but impure hypoglycemic extracts from the pancreas during the first two decades of the 20th century; but toxic side effects precluded their formal testing in diabetic patients.
- Insulin was discovered at the University of Toronto in 1921, through collaboration between Frederick G. Banting, Charles H. Best, James B. Collip and J.J.R. Macleod. Insulin was extracted from chilled pancreas in an acid / ethanol mixture; the extracts were found to lower blood glucose levels in pancreatectomised dogs and were first tested in a human diabetic (Leonard Thompson) in January, 1922.

Major advances in the understanding of diabetes and metabolism include:

- A. The sequencing of insulin in 1955 by Frederick Sanger and elucidation of its three dimensional structure in 1969 by Dorothy Hodgkin.
- B. The measurement of insulin concentration using the first radio immunoassay, by Solomon Berson and Rosalyn Yalow in 1959.
- C. The isolation of proinsulin in 1967 by Donald Steiner's group.
- D. Identification of specific insulin receptors by Pierre Freychet and colleagues in 1971, and
- E. The sequencing of the insulin receptor in 1985.

Mile stones in the management of diabetes include:

- A. The development of long acting insulin preparations (isophane) in 1936 by Hans Christian Hagedorn and colleagues.
- B. The testing of sulfonylureas in 1944 by Auguste Loubatieres.
- C. First therapeutic use of a biguanide (phenformin) in 1957 by G. Ungar.
- D. Introduction in the late 1970's of dry reagent test strips suitable for self monitoring of blood glucose, and
- E. Definitive proof from the diabetes control and complications trial (DCCT) published in 1993, that strict glycemic control could slow or prevent the development of diabetic microvascular complications.²³

Classification of diabetes and other categories of glucose regulation

Diabetes mellitus is classified on the basis of the pathogenic process that leads to hyperglycemia, as opposed to earlier criteria such as age of onset or type of therapy.^{2,24}

Etiologic classification of diabetes mellitus

I. Type 1 Diabetes (β -cell destruction, usually leading to absolute insulin deficiency)

- A. Immune-mediated
- B. Idiopathic

II. Type 2 diabetes (may range from predominantly insulin resistance with relative insulin deficiency to a predominantly insulin secretory defect with insulin resistance)

III. Other specific types of diabetes

A. Genetic defects of β -cell function characterized by mutations in :

1. Hepatocyte nuclear transcription factor (HNF) 4 α (MODY 1)
2. Glucokinase (MODY 2)
3. HNF – 1 α (MODY 3)
4. Insulin promoter factor (IPF) 1 (MODY 4)
5. HNF – 1 β (MODY 5)
6. Neuro D1 (MODY 6)
7. Mitochondrial DNA
8. Proinsulin or insulin conversion

B. Genetic defects in insulin action.

1. Type A insulin resistance
2. Leprechaunism
3. Rabson-Mendenhall syndrome
4. Lipodystrophy syndromes.

- C. Diseases of the exocrine pancreas – pancreatitis, pancreatectomy, neoplasia, cystic fibrosis, hemochromatosis, fibrocalculous pancreatopathy.
- D. Endocrinopathies – acromegaly, cushing’s syndrome, glucagonoma, pheochromocytoma, hyperthyroidism, somatostatinoma, aldosteronoma.
- E. Drug or chemical induced – Vacor, pentamidine, nicotinic acid, glucocorticoids, thyroid hormone, diazoxide, beta-adrenergic agonists, thiazides, phenytoin, interferon, protease inhibitors, clozapine, beta blockers.
- F. Infections – congenital rubella, cytomegalovirus, coxsackie.
- G. Uncommon forms of immune-mediated diabetes – “stiff-man” syndrome, anti-insulin receptor antibodies.
- H. Other genetic syndromes sometimes associated with diabetes – Down’s syndrome, Klinefelter’s syndrome, Turner’s syndrome, Wolfram’s syndrome, Friedreich’s ataxia, Huntington’s chorea, Laurence-Moon-Biedl syndrome, myotonic dystrophy, porphyria, Prader-Willi syndrome.

IV. Gestational diabetes mellitus (GDM)

The two broad categories of diabetes mellitus are designated as type 1 and type 2. Type 1 results from autoimmune beta cell destruction, which leads to insulin deficiency. Type 2 diabetes mellitus is a heterogenous group of disorders characterized by variable degrees of insulin resistance, impaired insulin secretion and increased glucose production. Distinct genetic and metabolic defects in insulin action and/or secretion give rise to the common phenotype of

hyperglycemia in type 2 diabetes mellitus.

Two features of the current classification of diabetes mellitus diverge from previous classifications. First, the terms 'insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) are obsolete.

Since many individuals with Type 2 diabetes mellitus eventually require insulin treatment for control of hyperglycemia, the term NIDDM generates considerable confusion. Second, age is not a criterion in the classification system. Although type 1 diabetes mellitus most commonly develops before the age of 30, an autoimmune beta cell destructive process can develop at any age. It is estimated that between 5 to 10% of individuals who develop diabetes mellitus after age of 30 have type 1 diabetes mellitus. Likewise, type 2 diabetes mellitus more typically develops with increasing age, but it also occurs in children, particularly in obese adolescents.

Spectrum of glucose homeostasis and diabetes²

Type of diabetes	Normal glucose tolerance	Hyperglycemia			
		Impaired fasting glucose or impaired glucose tolerance	Not insulin required	Insulin required for control	Insulin required for survival
Type 1					→
Type 2	←			→	
Other Specific types				→ - -	- - →
Gestational diabetes	←			→	
Time (years)					→
FPG (mg/dl)	< 110	110-125		126	
2-h pg (mg/dl)	< 140	140-199		200	

Type 1 diabetes mellitus

Immune Mediated Diabetes (Type 1A)

This form of diabetes, which accounts for only 5-10% of those with diabetes, results from a cellular mediated autoimmune destruction of the β -cells of pancreas. Markers of immune destruction of the β -cells include islet cell auto antibodies, autoantibodies to insulin, autoantibodies to glutamic acid decarboxylase (GAD65) and autoantibodies to the tyrosine phosphatases IA-2 and IA-2B. One and usually more of these auto antibodies are present in 85-90% of individuals when fasting hyperglycemia is initially recognized. Also the disease has strong HLA associations, with linkage to the DQA and DQB genes.

In this form of diabetes, the rate of β -cell destruction is quite variable. Being rapid in some individuals (mainly infants and children) and slow in others (mainly adults). Some patients, particularly children and adolescents, may present

with ketoacidosis as the first manifestation of the disease. Others have modest fasting hyperglycemia that can rapidly change to severe hyperglycemia and / or ketoacidosis in the presence of infection or other stress. Immune mediated diabetes commonly occurs in childhood and adolescence, but it can occur at any age, even in 8th and 9th decade of life.

Usually associated with other autoimmune disorders such as Grave's disease, Hashimoto's thyroiditis, Addison's disease, vitiligo, celiac sprue, autoimmune hepatitis, myasthenia gravis and pernicious anemia.

Idiopathic Diabetes (Type 1B)

Some patients of type 1 diabetes mellitus have no known etiologies. These patients have permanent insulinopenia and are prone to ketoacidosis, but have no evidence of autoimmunity. This forms only a minority of patients with type 1 diabetes mellitus. Most patients are of African or Asian ancestry.

Individuals with this form of diabetes suffer from episodic ketoacidosis and exhibit varying degrees of insulin deficiency between episodes.

This form of diabetes is strongly inherited, lacks immunological evidence for β -cell autoimmunity, and is not HLA associated.

Type 2 diabetes mellitus

This form of diabetes, which accounts for ~90-95% of those with diabetes, encompasses individuals who have insulin resistance and usually have relative (rather than absolute) insulin deficiency.

There are probably many different causes of this form of diabetes. Specific etiologies are not identified. Most patients with type 2 diabetes mellitus are obese, and obesity itself causes some degree of insulin resistance.

Ketoacidosis seldom occurs spontaneously. This form of diabetes frequently goes undiagnosed for many years, as the hyperglycemia develops gradually.

Nevertheless, such patients are at increased risk of developing macrovascular and microvascular complications. The risk of developing this form of diabetes increases with age, obesity, and lack of physical activity. It Occurs more frequently in women with prior GDM (Gestational diabetes mellitus), and individuals with hypertension or dyslipidemia. It is often associated with a strong genetic predisposition, more so than type 1 diabetes mellitus.

Other Specific Types of Diabetes Mellitus

Other etiologies of diabetes mellitus include specific genetic defects in insulin secretion or action, metabolic abnormalities that impair insulin secretion, mitochondrial abnormalities and a host of conditions that impair glucose tolerance. MODY (Maturity Onset Diabetes of Young) is a subtype of diabetes mellitus characterized by autosomal dominant inheritance, early onset of hyperglycemia, and impairment of insulin secretion.

Diabetes mellitus can result from pancreatic exocrine disease when the majority of pancreatic islets (>80%) are destroyed. Hormones that antagonize the action of insulin can lead to diabetes mellitus. Thus diabetes mellitus, is often a feature of endocrinopathies, such as acromegaly and Cushing's disease.

Gestational Diabetes Mellitus (GDM)

Glucose intolerance may develop during pregnancy. Insulin resistance related to the metabolic changes of late pregnancy increases insulin requirements and may lead to IGT. GDM occurs in approximately 4% of pregnancies. Most women revert back to normal glucose tolerance postpartum, but have a substantial risk (30%-60%) of developing diabetes mellitus later in life.²⁵

Epidemiology

Worldwide

It is estimated that 366 million people had DM in 2011; by 2030 this would rise to 552 million. The number of people with Type 2 DM is increasing in every country with 80% of people with DM living in low- and middle-income countries. DM caused 4.6 million deaths in 2011.²¹

The incidence of Type 2 DM varies substantially from one geographical region to the other as a result of environmental and lifestyle risk factors.⁷

According to The International Diabetes Federation,²⁶ the prevalence of diagnosed diabetes has more than doubled in the last three decades, largely because of the increase in obesity in United States. The top 10 countries in number of people with diabetes currently are India, China, the United States, Indonesia, Japan, Pakistan, Russia, Brazil, Italy, and Bangladesh. The greatest percentage increase in rates of diabetes will occur in Africa over the next 20 years. Unfortunately, at least 80% of people in Africa with diabetes are undiagnosed, and many in their 30s to 60s will die from diabetes there.²⁷

A 2011 Centers for Disease Control and Prevention (CDC) report estimated that nearly 26 million Americans have diabetes.²⁸ Additionally, an estimated 79 million Americans have prediabetes. Diabetes affects 8.3% of Americans of all ages, 11.3% of adults aged 20 years and older, and 25% of persons aged 65 and older, according to the National Diabetes Fact Sheet for 2011. About 27% of those with diabetes—7 million Americans—do not know that they have the disease. About 215,000 people younger than 20 years had diabetes (type 1 or type 2) in the United States in 2010.

Indian scenario

In the urban population, an Indian Council of Medical Research (ICMR) study in 1972 reported a prevalence of 2.3%²⁹ which rose to 12.1% in the year 2000.³⁰ More recently, Mohan et al. (2008) provided estimates from a nationwide surveillance study of T2DM and found that in urban areas there was a prevalence of 7.3% of known T2DM and a prevalence of 3.2% in peri-urban/slum areas.

The International Diabetes Federation (IDF) estimates the total number of diabetic subjects to be around 40.9 million in India and this is further set to rise to 69.9 million by the year 2025.³¹

It is clear that in the last two decades, there has been a marked increase in the prevalence of diabetes among both urban as well as the rural Indians, with a suggestion that Southern India has seen the sharpest increase. Subsequent studies confirmed this high prevalence of diabetes in urban south India. Although in rural India the prevalence of diabetes is much lower than in the urban population, even here the prevalence rates are rapidly rising, though clearly more studies are needed.³²

A study conducted by Zaman et al showed higher prevalence of diabetes (19.78%) in Karnataka³³ as well as Vijaykumar et al also showed higher prevalence of diabetes (12.5%) in Kerala, south India.³⁴

It is evident that there is a shift in age of onset to younger age groups, which is alarming and this could have adverse effects on the nation's economy. Hence, the early identification of at-risk individuals, appropriate intervention to

increase physical activity and changes in dietary habits could to a great extent help to prevent/delay the onset of diabetes and thus reduce the burden due to its associated complications in India.³²

Race

The prevalence of Type 2 Diabetes Mellitus varies widely among various racial and ethnic groups. Type 2 Diabetes Mellitus is becoming virtually pandemic in some groups of Native Americans and Hispanic people. The risk of retinopathy and nephropathy appears to be greater in blacks, Native Americans, and Hispanics.⁶²

Sex

Type 2 DM is slightly more common in older women than men.⁶² Data from the NFHS of 2005-06 suggested that the number of women who have diabetes ranges from 0.28% women in Rajasthan to 2.54% women in Kerala. Five states (Tamil Nadu, Goa, Tripura, West Bengal, and Delhi) have relatively high (>1.5%) number of women with T2DM. Rajasthan, Uttar Pradesh, Assam, and Maharashtra have T2DM prevalence levels below 0.5%. Among men, six states (Kerala, Goa, Tripura, West Bengal, Andhra Pradesh, and Sikkim) have prevalence level >1.5%. Five states (Kashmir, Mizoram, Himachal Pradesh, Rajasthan, Uttar Pradesh) have prevalence below 0.5% for men.

A recent study conducted by Zaman et al showed the prevalence of diabetes was more in women (22.04%) compared to men (16.06%) in Karnataka people.³³

Age

While Type 2 Diabetes Mellitus traditionally has been thought to affect individuals older than 40 years, it is being recognized increasingly in younger persons, particularly in highly susceptible racial and ethnic groups and obese individuals. In some areas, more Type 2 than Type 1 diabetes mellitus is being diagnosed in pre-pubertal children, teenagers, and young adults. Virtually all cases of diabetes mellitus in older individuals are Type 2.³⁵

Causes for Diabetic Pandemic

The Type 2 DM epidemic is tightly and consistently linked to that of obesity, both geographically and chronologically. Many factors like, urbanization and mechanization, together with globalization of western pattern of lifestyle, along with poverty, lack of education, low socio-economic status and inner city deprivation are emerging as significant risk factors for DM. Lack of breast feeding, low birth weight is associated with insulin resistance and Type 2 DM in adult life (especially in subjects who become obese) due to long term metabolic response during poor fetal nutrition.³⁶

Etiology

The etiology of type 2 diabetes mellitus appears to involve complex interactions between environmental and genetic factors. Presumably, the disease develops when a diabetogenic lifestyle (i.e., excessive caloric intake, inadequate caloric expenditure, obesity) is superimposed on a susceptible genotype.

The body mass index (BMI) at which excess weight increases risk for diabetes varies with different racial groups. For example, compared with persons of European ancestry, persons of Asian ancestry are at increased risk for diabetes at

lower levels of overweight.³⁷ Hypertension and pre-hypertension are associated with a greater risk of developing diabetes in whites than in African Americans.³⁸

In addition, an in-utero environment resulting in low birth weight may predispose some individuals to develop type 2 diabetes mellitus.³⁹⁻⁴¹ Infant weight velocity has a small, indirect effect on adult insulin resistance, and this is primarily mediated through its effect on BMI and waist circumference.⁴²

About 90% of patients who develop type 2 diabetes mellitus are obese. However, a large, population-based, prospective study has shown that an energy-dense diet may be a risk factor for the development of diabetes that is independent of baseline obesity.⁴³

Some studies suggest that environmental pollutants may play a role in the development and progression of type 2 diabetes mellitus.⁴⁴ A structured and planned platform is needed to fully explore the diabetes-inducing potential of environmental pollutants.

Secondary diabetes may occur in patients taking glucocorticoids or when patients have conditions that antagonize the actions of insulin (e.g., Cushing syndrome, acromegaly, pheochromocytoma).

Major risk factors

The major risk factors for type 2 diabetes mellitus are the following:⁴⁵

- Age greater than 45 years (though, as noted above, type 2 diabetes mellitus is
- occurring with increasing frequency in young individuals).

- Weight greater than 120% of desirable body weight.
- Family history of type 2 diabetes mellitus in a first-degree relative (e.g., parents or siblings).
- Hispanic, Native American, African American, Asian American, or Pacific Islander descent.
- History of previous impaired glucose tolerance (IGT) or impaired fasting glucose (IFG).
- Hypertension (>140/90 mm Hg) or dyslipidemia (HDL cholesterol level < 40 mg/dL or triglyceride level >150 mg/dL).
- Polycystic ovarian syndrome (which results in insulin resistance)

Genetic influences

The genetics of type 2 diabetes mellitus is complex and not completely understood. Evidence supports the involvement of multiple genes in pancreatic beta-cell failure and insulin resistance. Genome-wide association studies have identified dozens of common genetic variants associated with increased risk for type 2 diabetes mellitus.⁴⁶ Of the variants thus far discovered, the one with the strongest effect on susceptibility is the transcription factor 7–like 2 (*TCF7L2*) gene.

Identified genetic variants account for only about 10% of the heritable component of most type 2 diabetes.⁴⁸ An international research consortium found that use of a 40-SNP genetic risk score improves the ability to make an approximate 8-year risk prediction for diabetes beyond that which is achievable when only common clinical diabetes risk factors are used. Moreover, the predictive ability is better in younger persons (in whom early preventive strategies could delay diabetes onset) than in those older than 50 years.⁴⁷

Depression

Accumulating evidence suggests that depression is a significant risk factor for developing type 2 diabetes. Pan et al found that the relative risk was 1.17 in women with depressed mood and 1.25 in women using antidepressants.⁴⁸

Antidepressant use may be a marker of more severe, chronic, or recurrent depression, or antidepressant use itself may increase diabetes risk, possibly by altering glucose homeostasis or promoting weight gain.

In turn, type 2 diabetes has been identified as a risk factor for the development of depression. Depressive symptoms and major depressive disorder are twice as prevalent in patients with type 2 diabetes as in the general population.⁴⁹

Schizophrenia

Schizophrenia has been linked to the risk for type 2 diabetes. Dysfunctional signaling involving protein kinase B (Akt) is a possible mechanism for schizophrenia; moreover, acquired Akt defects are associated with impaired regulation of blood glucose and diabetes, which is overrepresented in first-episode, medication-naive patients with schizophrenia.⁵⁰

Preeclampsia and Gestational Hypertension

A population-based, retrospective cohort study of 1,010,068 pregnant women examined the association between preeclampsia and gestational hypertension during pregnancy and the risk of developing diabetes post partum.

Results showed the incidence rate of diabetes per 1000 person-years was 6.47 for women with preeclampsia and 5.26 for those with gestational hypertension, compared with 2.81 in women with neither condition. Risk was further elevated in women with preeclampsia or gestational hypertension comorbid with gestational diabetes.⁵¹

Pathogenesis

Insulin resistance and abnormal insulin secretion are central to the development of Type 2 DM. Although the primary defect is controversial, most studies support the view that insulin resistance precedes an insulin secretory defect but that diabetes develops only when insulin secretion becomes inadequate.

Genetic Considerations

Type 2 DM has a strong genetic component. The concordance of Type 2 DM in identical twins is between 70 and 90%. Individuals with a parent with Type 2 DM have an increased risk of diabetes; if both parents have Type 2 DM, the risk approaches 40%.

Insulin resistance, as demonstrated by reduced glucose utilization in skeletal muscle, is present in many non-diabetic, first-degree relatives of individuals with Type 2 DM. The disease is polygenic and multifactorial since in addition to genetic susceptibility, environmental factors (such as obesity, nutrition, and physical activity) modulate the phenotype. The genes that predispose to Type 2 DM are incompletely identified, but recent genome-wide association studies have identified several genes that convey a relatively small risk

for Type 2 DM (relative risk of 1.1 to 1.5). Most prominent is a variant of the transcription factor 7 like 2 gene that has been associated with type 2 diabetes in several populations and with impaired glucose tolerance in one population at high risk for diabetes. Genetic polymorphisms associated with type 2 diabetes have also been found in the genes encoding the peroxisome proliferators-activated receptor- α , inward rectifying potassium channel expressed in beta cells, zinc transporter expressed in beta cells, IRS, and calpain 10. The mechanisms by which these genetic alterations increase the susceptibility to type 2 diabetes are not clear, but several are predicted to alter insulin secretion. Investigation using genome-wide scanning for polymorphisms associated with Type 2 DM is ongoing.²

Pathophysiology

Type 2 DM is characterized by impaired insulin secretion, insulin resistance, excessive hepatic glucose production, and abnormal fat metabolism. Obesity, particularly visceral or central (as evidenced by the hip-waist ratio), is very common in Type 2 DM. In the early stages of the disorder, glucose tolerance remains near-normal, despite insulin resistance, because the pancreatic beta cells compensate by increasing insulin output.

As insulin resistance and compensatory hyperinsulinemia progresses, the pancreatic islets in certain individuals are unable to sustain the hyperinsulinemic state. IGT, characterized by elevations in postprandial glucose, then develops. A further decline in insulin secretion and an increase in hepatic glucose production lead to overt diabetes with fasting hyperglycemia. Ultimately, beta cell failure may ensue.² This leads to a decrease in glucose transport into the liver, muscle cells, and fat cells. There is an increase in the breakdown of fat with

hyperglycemia. The involvement of impaired alpha-cell function has recently been recognized in the pathophysiology of Type 2 DM.²¹




Figure 1. Metabolic changes during the development of type 2 diabetes mellitus²

As a result of this dysfunction, glucagon and hepatic glucose levels that rise during fasting are not suppressed with a meal. Given inadequate levels of insulin and increased insulin resistance, hyperglycemia results. The incretins are important gut mediators of insulin release, and in the case of GLP-1, of glucagon suppression. Although GIP activity is impaired in those with Type 2 DM, GLP-1 insulintropic effects are preserved, and thus GLP-1 represents a potentially beneficial therapeutic option. However, like GIP; GLP-1 is rapidly inactivated by DPP-IV in vivo.²¹

Two therapeutic approaches to this problem have been developed: GLP-1 analogues with increased half-lives, and DPP-IV inhibitors, which prevent the breakdown of endogenous GLP-1 as well as GIP. Both classes of agents have

shown promise, with potential not only to normalize fasting and postprandial glucose levels but also to improve beta-cell functioning and mass. Studies are ongoing on the role of mitochondrial dysfunction in the development of insulin resistance and etiology of Type 2 DM. Also very important is adipose tissue, as endocrine organ hypothesis (secretion of various adipocytokines, i.e., leptin, TNF-alpha, resistin, and adiponectin are implicated in insulin resistance and possibly beta-cell dysfunction).²¹

A majority of individuals suffering from Type 2 DM are obese, with central visceral adiposity. Therefore, the adipose tissue plays a crucial role in the pathogenesis of Type 2 DM. Although the predominant theory used to explain this link is the portal/visceral hypothesis giving a key role in elevated non-esterified fatty acid concentrations, two new emerging theories are the ectopic fat storage syndrome (deposition of triglycerides in muscle, liver and pancreatic cells). These two hypotheses constitute the framework for the study of the interplay between insulin resistance and beta-cell dysfunction in Type 2 DM as well as between our obesogenic environment and DM risk in the next decade.²¹

Screening²

Diabetes was originally identified by the presence of glucose in the urine. Almost 2,500 years ago it was noticed that ants were attracted to the urine of some individuals. In the 18th and 19th centuries the sweet taste of urine was used for diagnosis before chemical methods became available to detect sugars in the urine. Tests to measure glucose in the blood were developed over 100 years ago, and hyperglycemia subsequently became the sole criterion recommended for the diagnosis of diabetes. Initial diagnostic criteria relied on the response to an oral

glucose challenge, while later measurement of blood glucose in an individual who was fasting also became acceptable.

The most widely accepted glucose-based criteria for diagnosis are: fasting plasma glucose (FPG) ≥ 126 mg/dL or a 2-h plasma glucose ≥ 200 mg/dL during an oral glucose tolerance test (OGTT) on more than one occasion. In a patient with classic symptoms of diabetes, a single random plasma glucose ≥ 200 mg/dL is considered diagnostic. Before 2010 virtually all diabetes societies recommended blood glucose analysis as the exclusive method to diagnose diabetes. Notwithstanding these guidelines, over the last few years many physicians have been using HbA1C to screen for and diagnose diabetes.

Although considered the “gold standard” for diagnosis, measurement of glucose in the blood is subjected to several limitations, many of which are not widely appreciated. Measurement of HbA1C for diagnosis is appealing but has some inherent limitations.⁵²

These issues have become the focus of considerable attention with the recent publication of the Report of the International Expert Committee that recommended the use of HbA1C for diagnosis of diabetes,⁵³ a position that has been endorsed (at the time of writing) by the ADA,⁵⁴ the Endocrine Society, and in a more limited fashion by American Association of Clinical Endocrinologists/American College of Endocrinology.⁵⁵

Current criteria for the diagnosis of diabetes:⁵⁶

- HbA1C $\geq 6.5\%$. The test should be performed in a laboratory using a method that is National Glycohemoglobin Standardization Program

(NGSP)-certified and standardized to the Diabetes Control and Complications Trial (DCCT) assay.

- Fasting plasma glucose (FPG) ≥ 126 mg/dl (7.0mmol/l). Fasting is defined as no caloric intake for at least 8 h, or
- 2-h plasma glucose ≥ 200 mg/dl (11.1mmol/l) during an oral glucose tolerance test (OGTT). The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.
- In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥ 200 mg/dl (11.1 mmol/l).
- In the absence of unequivocal hyperglycemia, result should be confirmed by repeat testing.

Oral Glucose Tolerance Test

The OGTT evaluates the efficiency of the body to metabolize glucose and for many years has been used as the “gold standard” for diagnosis of diabetes. An increase in postprandial glucose concentration usually occurs before fasting glucose increases. Therefore, postprandial glucose is a sensitive indicator of the risk for developing diabetes and an early marker of impaired glucose homeostasis. Published evidence suggests that an increased 2-h plasma glucose during an OGTT is a better predictor of both all-cause mortality and cardiovascular mortality or morbidity than the FPG.⁵²

The OGTT is accepted as a diagnostic modality by the ADA, WHO/ International Diabetes Federation (IDF).⁵³ However, extensive patient preparation is necessary to perform an OGTT. Important conditions include, among others, ingestion of at least 150 g of dietary carbohydrate per day for 3

days prior to the test, a 10 to 16-h fast, and commencement of the test between 7:00 a.m. and 9:00 a.m.⁵²

In addition, numerous conditions other than diabetes can influence the OGTT. Consistent with this, published evidence reveals a high degree of intra-individual variability in the OGTT, with a CV of 16.7%, which is considerably greater than the variability for FPG.⁵² These factors result in poor reproducibility of the OGTT, which has been documented in multiple studies.⁵⁷ The lack of reproducibility, inconvenience, and cost of the OGTT led the ADA to recommend that FPG should be the preferred glucose-based diagnostic test.⁵³

Advantages

- Sensitive indicator of risk of developing diabetes.
- Early marker of impaired glucose homeostasis

Disadvantages

- Lacks reproducibility
- Extensive patient preparation
- Time-consuming and inconvenient for patients
- Unpalatable
- Expensive
- Influenced by numerous medications
- Subject to the same limitations as FPG, namely, sample not stable, needs to be performed in the morning.

WHO Diabetes criteria - Interpretation of Oral Glucose Tolerance Test (1999)⁵⁸

Glucose levels	Normal		Impaired fasting glycaemia (IFG)		Impaired glucose tolerance (IGT)		Diabetes Mellitus (DM)	
	Fasting	2hrs	Fasting	2hrs	Fasting	2hrs	Fasting	2hrs
(mmol/L)	<6.1	<7.8	≥6.1&<7.0	<7.8	<7.0	≥7.8	≥7.0	≥11.1
(mg/dl)	<110	<140	≥110&<126	<140	<126	≥140	≥126	≥200

ADA criteria for diagnosis of diabetes mellitus⁵⁴

The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus of the American Diabetes Association stated that diabetes can be provisionally diagnosed with any one of the three criteria listed below. In the absence of unequivocal hyperglycemia with acute metabolic decompensation the diagnosis should be confirmed, on a subsequent day, by any one of the same three criteria.

- A fasting plasma glucose of >126 mg/dl (after no caloric intake for at least 8 hours) or,
- A random plasma glucose of >200 mg/dl (taken at any time of day without regard to time of last meal) with classic diabetes symptoms: increased urination, increased thirst and unexplained weight loss or,
- An oral glucose tolerance test (OGTT) (75 gram dose) of >200 mg/dl for the two hour sample. Oral glucose tolerance testing is not necessary if patient has a fasting plasma glucose level of >126 mg/dl.

The Committee states that the fasting plasma glucose is the preferred test and recommends moving toward its universal use for testing and diagnosis because of its ease of administration, convenience, acceptability to patients, and lower cost in comparison to the OGTT.

Summarized Interpretation of Oral Glucose Tolerance Test (OGTT)

- 2 hour postload glucose < 140 mg/dl = normal glucose tolerance
- 2 hour postload glucose between 140 mg/dl and 199 mg/dl = impaired glucose tolerance
- 2 hour postload glucose > 200 mg/dl = provisional diagnosis of diabetes (Must be confirmed on a subsequent day by any of the above criteria for diagnosis of Diabetes Mellitus.)

Standards of medical care in diabetes

Diabetes is a chronic illness that requires continuing medical care and patient education to prevent acute complications and to reduce the risk of long term complications.²⁴

Initial Evaluation

Medical history

- Symptoms, results of laboratory tests, and special examination results related to the diagnosis of diabetes.
- Prior HbA1C records.
- Eating patterns, nutritional status, and weight history; growth and development in children and adolescents.
- Details of previous treatment programs, including nutrition and diabetes

self-management education, attitudes, and health beliefs.

- Current treatment of diabetes, including medications, meal plan, and results of glucose monitoring and patients use of data.
- Exercise history.
- Frequency, severity, and cause of acute complications such as ketoacidosis and hypoglycemia.
- Prior or current infections, particularly skin, foot, dental, and genitourinary infections.
- Symptoms and treatment of chronic eye; kidney; nerve; genitourinary (including sexual), bladder, and gastrointestinal function (including symptoms of celiac disease in type 1 diabetic patients); heart; peripheral vascular, foot and cerebrovascular complications associated with diabetes.
- Other medications that may affect blood glucose levels.
- Risk factors for atherosclerosis: smoking, hypertension, obesity, dyslipidemia, and family history.
- History and treatment of other conditions, including endocrine and eating disorders.
- Assessment for mood disorder.
- Family history of diabetes and other endocrine disorders.
- Lifestyle, cultural, psychosocial, educational, and economic factors that might influence the management of diabetes.
- Tobacco, alcohol, and / or controlled substance use.
- Contraception and reproductive and sexual history.

Physical examination

- Height and weight measurements (and comparison to norms in children and adolescents).
- Sexual maturation staging (during pubertal period).
- Blood pressure measurement, including orthostatic measurements when indicated, and comparison to age-related norms.
- Fundoscopic examination.
- Oral examination.
- Thyroid palpation.
- Cardiac examination.
- Abdominal examination (e.g. for hepatomegaly).
- Evaluation of pulses by palpation and with auscultation.
- Hand/finger examination.
- Foot examination.
- Skin examination (for acanthosis nigricans and insulin-injection sites).
- Neurological examination.
- Signs of diseases that can cause secondary diabetes (e.g. hemochromatosis, pancreatic disease).

Laboratory evaluation

- HbA1C.
- Fasting lipid profile, including total cholesterol, HDL cholesterol, triglycerides, and LDL cholesterol.
- Test for microalbuminuria in type 1 diabetic patients who have had

diabetes for at least 5 years and in all patients with type 2 diabetes; some advocate beginning screening of pubertal children before 5 years of diabetes.

- Serum creatinine in adults (in children if proteinuria is present).
- Thyroid stimulating hormone (TSH) in all type 1 diabetic patients; in type 2 if clinically indicated.
- Electrocardiogram in adults, if clinically indicated.
- Urinalysis for ketones, protein, sediment.

Referrals

- Eye exam, if indicated.
- Family planning for women of reproductive age.
- MNT, as indicated.
- Diabetes educator, if not provided by physician or practice staff.
- Behavioral specialist, as indicated.
- Foot specialist, as indicated.
- Other specialties and services as appropriate.

Recommendations for Adults with Diabetes

Summary of recommendations for adults with diabetes	
<i>Glycemic control</i>	
HbA1C	< 7.0%
Preprandial plasma glucose	90 – 130 mg/dl (5.0 – 7.2 mmol/l)
Postprandial plasma glucose	< 180 mg/dl (< 10.0 mmol/l)
<i>Blood Pressure</i>	< 130/80 mmHg
<i>Lipids</i>	
LDL	< 100 mg/dl (<2.6 mmol/l)
Triglycerides	< 150 mg/dl (<1.7 mmol/l)
HDL	> 40 mg/dl (> 1.1 mol/l)
<i>Key concepts in setting glycemic goals :</i>	
<ul style="list-style-type: none"> • Goals should be individualized. • Certain populations (children, pregnant women, and elderly) require special considerations. • Less intensive glycemic goals may be indicated in patients with severe or frequent hypoglycemia. • More stringent glycemic goals (i.e. a normal A1C < 6%) may further reduce complications at the cost of increased risk of hypoglycemia. • Postprandial glucose may be targeted if HbA1C goals are not met despite reaching preprandial glucose goals. 	

Complications of Diabetes

Diabetes has both acute and long term complications.² They are:

Acute

- Diabetic ketoacidosis
- Hyperglycemic Hyperosmolar state
- Hypoglycemia

Long term:

- Retinopathy
- Neuropathy
- Nephropathy
- Ischemic heart disease
- Cerebrovascular disease
- Peripheral vascular disease
- Hypertensia.
- Others

Infections

- UTI
- Tuberculosis
- Candidiasis – oral / vulvovaginal
- Mucormycosis
- Necrotising fasciitis
- Periodontitis
- Dupuytren's contracture
- Pseudogout

Diabetic Retinopathy

Diabetic retinopathy is the most frequent cause of blindness among adults aged 20-74 years. During the first two decades of disease, nearly all patients with type 1 diabetes mellitus and >60% with type 2 diabetes mellitus have retinopathy. In type 2 diabetes mellitus, 21% of patients have retinopathy at first diagnosis.

Classification⁵⁹

Non Proliferative Diabetic Retinopathy (NPDR)

1. *Mild NPDR*

At least one retinal microaneurysm and one or more of the following : retinal hemorrhage, hard exudates, soft exudates.

2. *Moderate NPDR*

Hemorrhages or microaneurysms or both in at least one quadrant and one or more of the following: soft exudates, venous beading and IRMA.

3. *Severe NPDR*

Hemorrhages or microaneurysms or both in all quadrants, venous beading in two or more quadrants, IRMA in at least one quadrant.

PDR

1. Early PDR

One or more of the following:

- NVE
- NVD
- Vitreous or preretinal hemorrhage
- NVE < ½ disc area.

2. High risk PDR

One or more of the following.

- NVD > ¼- ⅓ disc area
- NVD with vitreous or preretinal hemorrhage

- NVE > ½ disc area. Preretinal or vitreous hemorrhage.

3. Advanced PDR

High risk PDR, traction retinal detachment involving macula or vitreous hemorrhage obscuring ability to grade NVD or NVE.

- IRMA – Intraretinal microvascular abnormalities.
- NVE – Neovascularisation elsewhere.
- NVD – Neovascularisation disc.

Diabetic retinopathy progresses from mild non-proliferative abnormalities to moderate and severe non-proliferative diabetic retinopathy to proliferative diabetic retinopathy. Macular edema can develop at all stages of diabetic retinopathy. NPDR usually develops late in first decade or early 2nd decade of type – 2 diabetes mellitus. PDR usually develops within 5 years of NPDR.

Pregnancy, poor glycemic control, hypertension and cataract surgery accelerate these changes. UKPDS study revealed that for every percentage reduction of HbA1C (eg. From 8 to 7%), there was a 35% reduction in risk of retinopathy,¹⁹ and tight BP control (to < 150/85 mmHg) results in 34% reduction in progression of retinopathy.⁶⁰

Diabetic Nephropathy

Diabetes has become the most common single cause of end stage renal disease (ESRD) worldwide. About 20-30% of patients with type 1 or type 2 diabetes mellitus develop evidence of nephropathy, but in type 2 diabetes a considerably smaller fraction of these progress to ESRD. However, because of much higher prevalence of type 2 diabetes mellitus, these patients constitute over half of patients with nephropathy needing dialysis.²⁴

The diabetic nephropathy progresses from appearance of low but abnormal levels of ≥ 30 mg to 299 mg/day or $20\mu\text{g}/\text{min}$) albumin in urine (stage of microalbuminuria) to stage of macroalbuminuria / clinical albuminuria (≥ 300 mg/day or $\geq 200\mu\text{g}/\text{min}$) to ESRD. Progress from microalbuminuria to macroalbuminuria usually takes 10-15 years. ESRD develops in 50% of type 1 diabetic individuals with clinical nephropathy within 10 years and in 75% by 20 years. But in type 2 diabetes mellitus, even after 20 years of overt nephropathy only 20% progress to ESRD.

Screening for Microalbuminuria:

A test for the presence of urinary microalbumin should be performed at diagnosis in patients with type 2 diabetes mellitus and after 5 years of disease duration in those with type 1 diabetes mellitus, then repeated annually. Screening for microalbuminuria can be performed by three methods.

1. Measurement of the albumin to creatinine ratio in a random spot urine collection.
2. 24 hr Urine collection and measurement of albumin excretion.
3. Timed (e.g. 4 hr or overnight) collection.
4. 24 hr collection of urine is most reliable.

*Definitions of abnormalities in albumin excretion*²⁴

Category	Spot collection	24 Hr Collection	Timed Collection
	($\mu\text{g}/\text{mg}$ creatinine)	($\text{mg}/24$ hrs)	($\mu\text{g}/\text{min}$)
Normal	<30	< 30	< 20
Microalbuminuria	30 – 299	30-299	20-199
Clinical albuminuria	≥ 300	≥ 300	≥ 200

In addition to being the earliest manifestation of nephropathy, albuminuria is a marker of greatly increased cardiovascular morbidity and mortality in patients with either form of diabetes.⁶⁰

Diabetic Neuropathy

Diabetic neuropathy occurs in approximately 50% of individuals with long standing type 1 or type 2 diabetes mellitus. As with other complications of diabetes mellitus, the development of neuropathy correlates with the duration of diabetes and glycemic control.

Classification

Symmetric

1. Distal, primarily sensory polyneuropathy.
2. Autonomic neuropathy
3. Chronic proximal motor neuropathy

Asymmetric

1. Acute or subacute proximal motor neuropathy.
2. Cranial mononeuropathy
3. Truncal neuropathy
4. Entrapment neuropathies²

Also classified as follows (Watkin's and Edmond's classification)⁶¹

1. Progressive Neuropathies
 - Chronic sensory motor neuropathy
 - Autonomic neuropathy
2. Reversible Neuropathies
 - Mononeuropathies
 - Proximal motor neuropathy (Amyotrophy)
 - Cranial nerve palsies (III,IV,VI)
 - Truncal radiculopathies
 - Acute painful neuropathies
3. Pressure Palsies
 - Carpal tunnel syndrome.

The most common form of diabetic neuropathy is distal symmetric polyneuropathy. Most frequently presents with distal sensory loss. Hyperesthesia, paresthesia and dysesthesia can also occur.

Painful neuropathies may develop in these patients. Both an acute (lasting < 12 months) and a chronic form of painful diabetic neuropathy have been described. Individuals with long standing type 1 or type 2 diabetes mellitus may develop autonomic neuropathy. This can involve multiple systems, including the

cardiovascular, gastrointestinal, genitourinary systems. Resting tachycardia, orthostatic hypotension, gastroparesis, bladder emptying abnormalities, hyperhidrosis of upper extremities and anhidrosis of lower extremities – are features of diabetic autonomic neuropathy.

Cardiovascular Disease in Diabetes

Cardiovascular disease incidence is increased in individuals with type 1 or type 2 diabetes mellitus. The Framingham Heart Study revealed a marked increase in peripheral arterial disease, coronary artery disease, myocardial infarction, congestive heart failure and sudden death (risk increases from one to five fold) in diabetes mellitus.⁶² The American Heart Association recently designated type 2 diabetes mellitus as a coronary risk equivalent i.e. they have a similar 10 year risk of MI, as those who have had a prior MI.²⁴ Because of extremely high prevalence of underlying cardiovascular disease in patients with type 2 diabetes mellitus, evidence of atherosclerotic vascular disease should be sought in a diabetic who has symptoms suggestive of cardiac ischemia, peripheral or carotid artery disease, a resting ECG indicative of prior MI, plans to initiate an exercise program, proteinuria or two other cardiac risk factors. (ADA recommendations).²⁴

In addition to coronary artery disease, cerebrovascular disease is increased in individuals with diabetes mellitus (three fold increase in stroke). Proof that improved glycemic control reduces cardiovascular complications in diabetes mellitus is lacking.⁶³

Overall, diabetes is a metabolic disease that can affect nearly every organ system in the body. Diabetes continues to be a public health concern. Although important knowledge has been acquired on the etiology of diabetes its precise

etiopathogenesis is still under discussion. Inflammatory factors, reactive oxygen species and autoimmune reactions have all strongly emerged as the major pathogenic effectors for diabetes. Recently, Vitamin D has sparked widespread interest in the pathogenesis and prevention of diabetes. As the major regulator for calcium homeostasis, Vitamin D directly and or indirectly improves insulin exocytosis via activating calcium-dependent endopeptidases. Vitamin D also improves glucose tolerance.⁶⁴ Vitamin D could also prevent type 2 diabetes through its role as an efficient antioxidant.

Additionally, the steroid hormone form of Vitamin D promotes suppressor cell activity and inhibits the generation of cytotoxic (Tc), macrophages, delayed hypersensitivity type and natural killer (NK) cells.⁶⁵

Vitamin D also mediates several non-calcemic functions. It is a regulator of cellular proliferation, differentiation and replication, and mediator of autoimmune reactions, in a variety of organs and biological systems. The discovery of receptors for $1\alpha, 25$ - dihydroxyvitamin D3 (1,25(OH)₂D₃), the activated form of Vitamin D, in tissues with no direct role in calcium and bone metabolism (e.g., pancreatic beta-cells and cells of the immune system) has broadened our view of the physiological role of Vitamin D.

Vitamin D

Vitamin D was first identified and characterized in 1923 by Goldblatt and Soames.⁶⁷ It is an essential vitamin naturally produced by the body on exposure to sunlight.




Figure 2. Molecular structures of vitamin D2 (ergocalciferol) and vitamin D3 (Cholecalciferol)²⁰

The term Vitamin D encompasses secosterols, ergocalciferol (VD₂) and cholecalciferol (VD₃). Vitamin D₂ is produced commercially by irradiation of plant sterols (ergosterol), whereas Vitamin D₃ is primarily manufactured in the skin from 7-dehydro cholesterol via photochemical synthesis using UV radiation from sunlight and can also be found in food of animal origin. The best food sources of Vitamin D are cod liver oil, fatty fish, and egg yolks.

Metabolism of Vitamin D

Natural Vitamin D by itself has no hormonal activity. To become biologically active, Vitamin D needs two successive hydroxylations one in the liver (at carbon 25) and another in the kidney (at a position of carbon 1). In the liver Vitamin D is hydroxylated at carbon 25 to 25-hydroxy Vitamin D (25(OH)D). Circulating 25(OH)D concentrations are considered an indicator of

Vitamin D status. In the kidneys, 25-hydroxy Vitamin D (25(OH)D) is converted to an activated (1,25-dihydroxy vitamin D; 1,25(OH)₂D). This is the biologically active form of Vitamin D.²⁰




Figure 3. Synthesis and metabolism of Vitamin D. Vitamin D can be obtained from food (vitamin D2 and D3) or by photobiogenesis in the skin (vitamin D3). In the blood, all Vitamin D metabolites are bound to Vitamin D-binding protein (DBP). Vitamin D3 is converted by two successive hydroxylations in the liver (25-hydroxylases) and kidney (1 α -hydroxylase) into its active hormonal form,



The production of 1,25(OH)₂D₃ in the kidney is regulated by several factors, particularly by levels of parathyroid hormone, although kidney 1 α -hydroxylase is also subject to direct negative feedback inhibition by 1,25(OH)₂D₃. The proximal renal tubule is the principal site of 1 α -hydroxylation, although high levels of 1 α -hydroxylase mRNA have also been

found in human keratinocytes, dendritic cells and macrophages.

Another hydroxylation enzyme, 24-hydroxylase, initiates the catabolic cascade of 25-hydroxyvitamin D₃ and 1,25(OH)₂D₃. In the circulation, all metabolites of vitamin D are bound to a carrier protein known as Vitamin D-binding protein (DBP).⁶⁶

Molecular action of 1,25-dihydroxyvitamin D₃

The Vitamin D hormone exerts its effects mainly by activating the nuclear Vitamin D receptor (VDR), a member of the nuclear receptor super-family of ligand activated transcription factors. In humans the gene encoding the VDR is located on chromosome 12cen-q12. The binding of 1,25(OH)₂D₃ to the VDR leads to the transcription of genes regulated by 1,25(OH)₂D₃. The mechanism of this transcriptional regulation is very complex and is only just beginning to be unraveled.




Figure 4. Genomic actions of 1,25-dihydroxyvitamin D₃²⁰

Molecules of 1,25(OH)₂D₃ penetrate the plasma membrane with the help of DBP and exert their genomic effects by activating the VDR. Ligand binding to the VDR induces a conformational change in the receptor and subsequent heterodimerization with RXR. The RXR-VDR complex binds to the VDRE, which is located within the 5' flanking region of target genes. Thereafter, co-repressor (CoR) proteins are released from the surface of the VDR, allowing interaction with co-activator (CoA) proteins. These molecules modulate chromatin structure and allow the interaction of the receptor with the RNA polymerase II transcriptional complex (POL II), thus activating transcription of the target gene.

The cognate Vitamin D response element (VDRE) to which the VDR binds consists of a hexanucleotide direct repeat spaced by three nucleotides (DR3-type VDRE). The VDR usually binds as a heterodimer with the retinoic X receptor (RXR), and the classical effects of 1,25(OH)₂D₃ are the result of interactions with this nuclear receptor.

With respect to its relevance in diabetes, the classical VDRE and other response sites are found within genes encoding proteins with important functions in beta-cells and within genes encoding proteins with key roles throughout the immune system, such as cytokines and transcription factors.⁶⁸

Vitamin D deficiency

Serum 25(OH)D is the best indicator of Vitamin D body store levels. The desirable concentration of Vitamin D in normal healthy adult should be greater than 30 ng/ml. Vitamin D deficiency is characterized by circulating levels of

25(OH)D less than 20 ng/ml. Concentrations ranging between 20-30 ng/ml are often considered insufficient.⁶⁹

Vitamin D deficiency is a common problem and the clinical consequences are protean. Low Vitamin D status can be caused by number of factors, including insufficient cutaneous synthesis (due to limited sunlight exposure or aging), inadequate intake and absorption of Vitamin D, obesity or darker skin. Low blood levels of its main metabolite, 25(OH) D, have been linked to poor health outcomes such as fractures, poor physical function, sarcopenia, diabetes, osteoporosis, cancer, cardiovascular, neurodegenerative, autoimmune and infectious diseases.⁷⁰

Vitamin D and Type 2 Diabetes

Type 2 diabetes is characterized by insulin resistance and altered insulin secretion. The role of Vitamin D in type 2 diabetes is suggested by a seasonal variation in glycemic control reported in patients with type 2 diabetes, being worse in the winter,⁶⁶ which may be due to prevalent hypovitaminosis D as a result of reduced sunlight in winter. Several studies have demonstrated a link between Vitamin D and the incidence of type 2 diabetes. In a recent study, de Boer et al,⁷¹ examined the effect of calcium plus Vitamin D supplementation on the incidence of drug-treated diabetes in postmenopausal women and concluded that, calcium plus Vitamin D3 supplementation did not reduce the risk of developing diabetes over seven years of follow-up in this randomized, placebo controlled trial. However, they suggested that, higher doses of Vitamin D might be required to affect diabetes risk. In support of this argument, in Nurses Health Study - a large prospective, observational cohort, women with the highest calcium and Vitamin D intake (> 1200 mg and > 800 IU daily, respectively) had a 33% lower

risk of incident type 2 diabetes mellitus than women with the lowest calcium and Vitamin D intake (< 600 mg and < 400 IU daily, respectively).⁷²

Another large cohort study from Finland indicated inverse association between serum 25(OH)D₃ and risk of type 2 diabetes. These results were consistent with those from the Nurses' Health Study by Pittas et al,⁶⁵ where an inverse association was observed for the intake of Vitamin D supplements.

However, these studies were not able to differentiate whether the results were due to the effect of Vitamin D deficiency on beta-cell function or on insulin resistance. Several reports have ascribed an active role to Vitamin D in the functional regulation of the endocrine pancreas, particularly the beta-cells. Not only are receptors for 1,25(OH)₂D₃ found in beta-cells, but the effector part of the Vitamin D pathway is also present in the form of Vitamin D-dependent calcium binding protein, also known as calbindin-D_{28k}. The expression of calbindin-D_{28K} has been shown to protect beta-cells from cytokine-mediated cell death,⁶⁶ thereby reducing the risk of type 2 diabetes.

Mechanisms of action of Vitamin D on Type 2 diabetes

Vitamin D and the beta-cell

There are several lines of evidence supporting a role for Vitamin D in pancreatic beta-cell function. Sheena et al⁷³ examined the cross-sectional association between vitamin D and beta-cell dysfunction in subjects at risk for type 2 diabetes and showed a positive association between Vitamin D and beta-cell function. A high prevalence of hypovitaminosis D was noted among women with type 2 diabetes. Hyper responsive insulin secretion after a glucose challenge has been found in older men with hypovitaminosis D.⁷⁴

Vitamin D may act in two possible pathways; Vitamin D may act directly to induce beta-cell insulin secretion by increasing the intracellular calcium concentration via non-selective voltage-dependent calcium channels or it may mediate activation of beta-cell calcium-dependent endopeptidases to produce the cleavage that facilitates the conversion of proinsulin to insulin. In peripheral insulin-target tissues, Vitamin D might directly enhance insulin action through stimulation of the expression of insulin receptors and regulation of insulin-mediated intracellular processes via regulation of the calcium pool.⁶⁶

Insulin resistance

Insulin resistance is a recognized precursor for the development of type 2 diabetes. Vitamin D may have a beneficial effect on insulin action either directly, by stimulating the expression of insulin receptors thereby enhancing insulin responsiveness for glucose transport, or indirectly via its role in regulating extracellular calcium ensuring normal calcium influx through cell membranes and adequate intracellular cytosolic calcium $[Ca^{2+}]_i$ pool. Calcium is essential for insulin-mediated intracellular processes in insulin-responsive tissues such as skeletal muscle and adipose tissue with a very narrow range of $[Ca^{2+}]_i$ needed for optimal insulin-mediated functions. Changes in $[Ca^{2+}]_i$ in primary insulin target tissues may contribute to peripheral insulin resistance via impaired insulin signal transduction leading to decreased GLUT-4 activity.²⁰

Associations between low Vitamin D level and decreased insulin sensitivity have been reported in cross-sectional studies. A recent study by Enju Liu et al⁶⁹ examined the association between Vitamin D status and insulin resistance in non-diabetic individuals and showed that higher Vitamin D status was

inversely associated with fasting markers of insulin resistance.

A positive correlation of 25(OH)D concentration with insulin sensitivity and a negative effect of hypovitaminosis D have been reported by Ken C Chiu et al.⁷⁵

Some observational^{71,75} studies have shown an inverse association between Vitamin D-calcium status and insulin resistance. Results from randomized trials on the effect of Vitamin D and/or calcium supplementation on insulin resistance show either improvement⁷⁵⁻⁷⁷ or no effect⁷⁸ of insulin action with supplementation.

Inflammation

Type 2 Diabetes is associated with systemic inflammation. Systemic inflammation has been linked primarily to insulin resistance but elevated cytokines may also play a role in beta-cell dysfunction by triggering beta-cell apoptosis. Vitamin D may improve insulin sensitivity and promote beta-cell survival by directly modulating the generation and effects of cytokines. Vitamin D interacts with Vitamin D response elements in the promoter region of cytokine genes to interfere with nuclear transcription factors implicated in cytokine generation and action. Vitamin D can down regulate the activation of NF- κ B, which is an important regulator of genes encoding pro-inflammatory cytokines implicated in insulin resistance. Vitamin D interferes with cytokine generation by upregulating expression of calbindin, a cytosolic calcium-binding protein found in many tissues including pancreatic beta-cells. Calbindin has been shown to protect against cytokine-induced apoptosis that may occur after a rise in cytosolic free calcium [Ca²⁺]_i.²⁰ There is very limited and conflicting data from human studies that has directly examined the relationship between Vitamin D or calcium status and systemic

inflammation in relation to type 2 Diabetes.⁶⁵

Vitamin D and Glucose Transport

Insulin stimulates glucose metabolism in its target tissues via recruitment of transporters from a large intracellular pool to the plasma membrane. The functional activity of these transporters has been shown to be impaired in diabetes. As Vitamin D modulates insulin secretion, it is reasonable that Vitamin D deficiency may in part contribute to the altered expression of these transporters. Although the role of Vitamin D in diabetes is well recognized, its relation to glucose transport is not well studied.²⁰

Consuelo et al⁷⁹ observed the effect of Vitamin D on glucose transport in adipocytes in non-diabetic and streptozotocin induced diabetic rats. Treatment with 1,25(OH)₂D₃ to non-diabetic rats did not alter basal and insulin stimulated glucose transport in adipocytes from these animals. The treatment with Vitamin D to streptozotocin induced diabetic rats, improved the decreased basal glucose transport by 107% and the insulin stimulated glucose transport in adipocytes by 71% from these diabetic animals. The Possible mechanism is likely to be the indirect effect of Vitamin D. Vitamin D contributes to normalization of extracellular calcium ensuring normal intracellular calcium pool as elevated intracellular calcium impairs insulin receptor phosphorylation leading to impaired insulin signal transduction and decreased GLUT-4 activity.

Peeyush et al⁸⁰ examined the effect of Vitamin D supplementation on preventing the altered expression of GLUT-3 in STZ-induced diabetic rats leading to imbalanced glucose transport in the neurons of cerebellum. They

observed that treatment with Vitamin D and insulin, stabilized the glucose transport mechanism mediated through GLUT-3 in the cerebellum. They concluded that supplementation with Vitamin D to STZ-induced diabetic rats has beneficial effects in reducing the alterations in GLUT-3 and imbalanced glucose utilization in cerebellum. However large, well-controlled, randomized studies are required to define the relationship between Vitamin D and glucose transport.

Vitamin D and Complications of Diabetes

Diabetes is associated with complications such as cardiovascular disease, renal impairment, and peripheral neuropathies. Studies in the past have explored the relationship of Vitamin D concentrations to these complications. The earliest evidence for the relationship of Vitamin D concentration to cardiovascular disease began with diabetic patients who had end stage renal disease. It was found that in patients having dialysis the cardiovascular mortality was 10 to 20 times higher than the general population. The severe hypertension in diabetic patients was attributed to the reduced synthesis of calcitriol by the kidneys. When patients were given 1 alpha-vitamin D and the Vitamin D analogue paricalcitol, it was noted that the mortality rate for cardiovascular disease was significantly reduced.⁸¹

A study on 825 US hemodialysis patients to determine the relationship between Vitamin D levels and mortality reported that 78% of the patients were Vitamin D deficient and that this was associated with an increased early mortality.⁸²

Zhang et al⁸³ reported that receptor-mediated Vitamin D actions may be protective of kidneys in rats with diabetic nephropathy. This suggests that

Vitamin D may be useful and preventative for the kidneys. In a study to determine the relationship between 25(OH) D and kidney functions on NHANES III participants, the level of 25(OH)D was significantly lower in persons with severely decreased glomerular filtration rate when compared with those with normal kidney function.⁸⁴

Diabetes has been associated with several neurological disorders including reduced locomotor activity which in turn is associated with low concentration of Vitamin D.⁸⁵

A study by Peeyush KT⁸⁶ reported the altered expression of cholinergic and dopaminergic receptors in the central nervous system of STZ-induced diabetic rats. They further suggested that the altered expression of these receptors was brought back to control by the treatment with Vitamin D.

A small, clinical study of 51 patients with type 2 diabetes (37 female) evaluated neuropathic complaints such as pain, burning, tingling, numbness, and throbbing sensations. Patients who were Vitamin D deficient at base line were given cholecalciferol (D3) and re-evaluated at 3-month follow-up. Serum concentrations increased 67.4% from 18 to 30 ng/mL, and were associated with significantly lower pain scores.⁸⁷ These findings provide a confirmatory evidence for neuroprotective role of Vitamin D and represent a novel possibility for the better management of diabetic mediated complications.

Overall, the published literature supports a possible role of Vitamin D in the pathogenesis and prevention of diabetes. Vitamin D deficiency appears to be detrimental to beta-cell function, and leads to glucose intolerance in animal models and humans, and consequently type 2 diabetes. Vitamin D deficiency in early life predisposes NOD mice and humans to the later development of

autoimmune diabetes. Several Vitamin D related genes have shown association with different pathogenetic traits of the disease. Vitamin D and its related metabolic and immune pathways may be involved in the pathogenesis of diabetes at environmental and genetic levels.²⁰

Recent Literature on Role of Vitamin D in Diabetes Mellitus

The effect of Vitamin D supplementation was studied by Avaneil et al.⁸⁸ In sum, 7 out of 8 studies found a significant association between diabetes and Vitamin D, and the study from Avaneil et al⁸⁸ didn't rule out a protective role of Vitamin D.

In a cross-sectional study from Renzaho et al⁸⁹ the demographics were described of 49 African migrants living in Melbourne. In 88% of the participants Vitamin D insufficiency occurred and the participants were at high risk for developing type 2 diabetes or cardiovascular disease. The risk was measured by measuring the following factors: being overweight, hypertension, insulin resistance and cholesterol. Considering the voluntary nature of the study, and the small number of participants, the results cannot be easily generalized to a bigger community. The authors suggest that a study with Vitamin D intervention can give more evidence for the existing relationship between Vitamin D and type 2 diabetes.

In a cross-sectional population based study from Shankar et al⁹⁰ 12,719 US adults who filled out the National Health and Nutrition Examination Survey were used. Adjustments were made for age, sex, season, race, smoking, geographic region, alcohol intake, BMI, physical activity, Vitamin D intake, hypertension and cholesterol. Compared with the highest quartile, the odds ratio of

pre-diabetes for the lowest quartile was 1.47 (1.16–1.85) $p = 0.001$. The conclusion from this study is; low levels of Vitamin D are associated with pre diabetes in US adults. In a longitudinal cohort study in 4,097 Finland survey participants examined by Mattila et al⁹¹ the relation between serum 25(OH)D levels and subsequent risk of type 2 diabetes was observed. Adjustments were made for age, sex and month when the blood samples were collected. After a follow-up of 17 years the relative risk of diabetes for the highest quartile compared to the lowest quartile of serum 25(OH)D was 0.60 (0.36-0.98) $p=0.01$, showing that higher levels of 25(OH)D were associated with a significant decreased diabetes risk. Thus high Vitamin D levels are good. When further adjustments were made for BMI, smoking, education and exercise the relative risk was no longer significant: 0.70 (0.42-1.16) $p=0.07$. These findings showed a significant positive association between high levels of Vitamin D and decreased risk of developing type 2 diabetes.

Liu et al⁹² used a subsample of the Framingham Offspring Study to examine the relation between Vitamin D status and incidence of type 2 diabetes. Adjustments were made for age, sex, waist circumference, parental history of type 2 diabetes, hypertension, cholesterol, impaired fasting glucose and diet. In this prospective cohort study, the plasma 25(OH) D levels from 3066 participants were collected. In total 133 participants developed type 2 diabetes after 7 years. Compared to the lowest quartile, those in the highest quartile of predicted 25(OH) D levels had a 40% lower incidence for developing type 2 diabetes HR: 0.60 (0.37-0.97) ($p = 0.03$). They suggested that maintaining the Vitamin D status can lower the risk of developing type 2 diabetes.

The correlation between sun exposure and type 2 diabetes was analyzed by

Lindqvist et al⁹³ in a prospective cohort study. During an 11 year follow-up 24,098 Swedish women answered an inquiry. Women with active sun exposure were at 30% less risk for developing type 2 diabetes, compared to the women with non-active sun exposure. Also the women with more sun exposure had a lower risk (ranging from 40-60%) of developing type 2 diabetes. A possible explanation is that BMI is a high risk for type 2 diabetes, and Vitamin D influences this. Overall, this study supports that sunlight is involved in glucose metabolism, and BMI appears to mediate this association.

In a prospective population based study from Grimnes et al⁹⁴ 6119 Norwegian citizens were included. During an 11 year follow-up period, the risk of developing type 2 diabetes was measured in relation to Vitamin D levels. Adjustments were made for age, sex, BMI, physical activity and smoking behavior. Vitamin D levels were measured every month, and diabetes was defined using a hospital journal-based end-point registry. The risk for the development of diabetes in the highest quartile was used as reference, the hazard ratios for the third, second and first quartiles were: non smokers: 1.00 (0.62–1.61), 1.50 (0.97–2.31) and 1.89 (1.25–2.88), smokers: 1.79 (0.77–4.19), 2.33 (1.02–5.35) and 2.68 (1.18–6.08). In this analysis the ratios were adjusted for age and sex. Adjustments for BMI rendered the findings nonsignificant. The conclusion of this study is that the risk of developing type 2 diabetes increases when Vitamin D levels are low, but this may be partially mediated by, once again, BMI. Pittas et al⁹⁵ examined 83,779 female nurses in a prospective study. The purpose of this study was to determine the relation between Vitamin D and calcium intake and the risk of developing type 2 diabetes. During a 20 year follow-up 4,843 cases of type 2 diabetes were documented. Adjustments were

made for age, sex, smoking, BMI, physical activity, family history of diabetes, hypertension and alcohol consumption. The RR for type 2 diabetes was 0.87 (0.75–1.00) $p = 0.04$, comparing the highest with the lowest category of Vitamin D from supplements assessment. When adjusted for the confounding factors, no relationship was found. However, the relative risk for type 2 diabetes was: 0.67 (0.49–0.90) when comparing the daily intake of Vitamin D >800 IU and calcium 1,200 mg versus <400 IU Vitamin D and 600 mg calcium. Thus Vitamin D and calcium may play a role in the development of type 2 diabetes.

Eight articles were discussed regarding the relation between Vitamin D and diabetes. Two cross-sectional studies from Renzaho et al⁸⁹ and Shankar et al⁹⁰ found that low Vitamin D levels have been associated with risk of having diabetes. The prospective studies from Pittas et al,⁹⁵ Liu et al⁹² and Lindqvist et al⁹³ found a higher risk of developing diabetes when Vitamin D levels are low. Mattila et al⁹¹ found a significant inverse association between Vitamin D and diabetes in a longitudinal design. These findings from Mattila support the statement that Vitamin D insufficiency leads to and precedes diabetes. Grimnes et al⁹⁴ found a significant higher risk of developing diabetes when Vitamin D was low, but not if controlled for BMI. The intervention study from Avanell et al⁸⁸ found no significant effect from Vitamin D supplementation on the risk of developing type 2 diabetes mellitus. The authors noted that the Vitamin D supplements didn't contain high levels of Vitamin D, which may have influenced the results.

Overall, studies on Vitamin D supplementation on prevention of diabetes are inconclusive. However robust clinical data is required to support a role for Vitamin D supplementation in the prevention of diabetes.

MATERIALS AND METHODS

The present study was conducted in the Department of Medicine, BLDE University's Shri B M Patil medical college and research center , Bijapur from January 2013 to June 2014 on newly detected and known patients with type 2 diabetes mellitus.

Study design

The study design was one and half year cross sectional study.

Study period and duration

The present one and half year study was conducted from January 2013 to June 2014

Place

The present study was conducted in Department of Medicine, BLDE University's Shri B M Patil medical college and research center , Bijapur.

Source of Data

Patients with type 2 diabetes mellitus of BLDE University's Shri B M Patil medical college and research center, Bijapur were studied.

Sample size

A total of 125 patients with type 2 diabetes mellitus were selected for the study.

Sampling procedure

- With prevalence of Type 2 Diabetes Mellitus – 9%⁸
- At confidence interval of 95% allowing ± 5 margin of error
- The calculated sample size was 125 using the below statistical formula.

$$n = \frac{(1.96)^2 (p) (1-p)}{d^2}$$

Hence a sample size of 125 patients with type 2 diabetes mellitus was considered.

Selection criteria

Inclusion criteria

- Patients with type 2 diabetes mellitus.
- Age more than 18 years.

Exclusion criteria

- Age less than 18 years.
- Patients with chronic renal failure which corresponds to chronic kidney disease stages 3-5 (glomerular filtration rate < 60ml/min per 1.73 m².)
- Patients taking vitamin D supplements

Ethical clearance

The ethical clearance was obtained from Institutional Ethics Committee, BLDE University's Shri B M Patil medical college and research center , Bijapur.

Informed Consent

The patients fulfilling selection criteria were explained about the nature of the study. Those willing to participate were enrolled in the study after obtaining a written informed consent (Annexure 11).

Method of collection of data

Demographic data such as age, sex and occupation were recorded. Patients were interviewed and history regarding type 2 diabetes mellitus such as duration of disease, medication, personal history and history pertaining to the other comorbid conditions was obtained. Further these patients were subjected to a thorough physical examination such as anthropometry (including height and weight), vitals (pulse rate, blood pressure and respiratory rate) and systemic examination. These findings were recorded on a predesigned and pretested proforma (Annexure III).

Investigations

The selected patients underwent the following investigations.

Complete blood count.

- Renal function test.
- Liver function test.
- Urine – Routine and microscopy.
- Blood sugar levels – Fasting and post prandial
- Glycated haemoglobin (HbA1c)
- Fundoscopy
- Fasting lipid profile
- Fasting Serum 25-hydroxy Vitamin D

Fasting Serum 25-hydroxy Vitamin D

The estimation of Vitamin D was done using Siemens, ADVIA Centraur VitD assay, a one pass 18 minute antibody competitive immunoassay that used an anti fluorescein monoclonal mouse antibody covalently bound to paramagnetic particles and anti 25 (OH) Vitamin D monoclonal mouse antibody labeled with acridinium ester and a Vitamin D analog labeled with fluorescein.⁹⁶

Outcome variables

Body mass index

A thorough clinical examination was conducted. Height and weight was recorded and body mass index was calculated based on formula;

$$\text{Body Mass Index} = \frac{\text{Weight (Kg)}}{\text{Height}^2 \text{ (m)}}$$

Body mass index was classified according to Overweight and obesity by BMI in

adult Asians as below.⁹⁷

Classification	BMI (Kg/m²)	Risk of co-morbidities
Underweight	< 18.5	Low (But increased risk of other clinical problems)
Normal range	18.5 to 22.9	Average
Overweight	> 23	
At risk	23.0 to 24.9	Increased
Obese I	25.0 to 29.9	Moderate
Obese II	≥ 30.0	Severe

Lipid profile

Total cholesterol, triglycerides, HDL, LDL levels were noted and the findings were recorded. Normal values of lipid parameters were interpreted as;

- Low density lipoprotein < 100 mg/dL.
- High density lipoprotein < 40 mg/dL
- Total Cholesterol < 200 mg/dL.
- Triglycerides < 150 mg/dL.

Fasting Serum 25-hydroxy Vitamin D

The results were interpreted as below.

- < 20 ng/ml – Deficiency
- ≥ 20 to 30 ng/ml – Insufficiency
- 30 ng/ml – Normal

Statistical analysis

The data obtained was coded and entered into Microsoft Excel Worksheet

(Annexure I V). The categorical data was expressed as rates, ratios and proportions and comparison was done using chi-square test. The continuous data was expressed as mean \pm standard deviation (SD) and comparison was done by two sample 't' test with unequal variance. A probability value ('p' value) of less than or equal to 0.05 was considered as statistically significant.


OBSERVATIONS AND RESULTS

The present cross sectional study titled **“A study on the associational between HbA1C and Vitamin - D in type 2 Diabetes Mellitus”** was carried out in Department of Medicine, Shri. B.M. Patil medical college and Research Centre, Bijapur.

A total 125 patients were studied. The findings / observations and final results are tabulated below.

Table - 1. Age Distribution


Age group (Years)	Distribution (n=125)	
	Number	Percentage
≤ 40	5	4.00
41 to 50	19	15.2
51 to 60	40	32.00
61 to 70	36	28.8
71 to 80	19	15.2
> 80	6	4.8
Total	125	100.0



Patients age ranged from 39 to 85 years, maximum number of cases were in the age group of 51 to 60 that is 40 patients (32%), between 61 to 70 years 36 patients (28.8%) and between 41 to 50 years and 71 to 80 years 19 patients (15.2%) in each group. The mean age of study population was 60.22 ± 11.65 years.

Table - 2. Sex Distribution

Sex	Distribution (n=125)	
	Number	Percentage
Male	77	61.6
Female	48	38.4
Total	125	100.0




Out of 100 patients 77 (61.6%) were males and 48 patients (38.4%) were females, accounting a ratio of male to female 1.60:1.

Inference : Male preponderance was observed.

Table - 3. Duration of diabetes


Duration of diabetes	Distribution (n=125)	
	Number	Percentage
Newly detected	16	12.8
Upto 5	36	25.8
6 to 10	37	26.9
11 to 15	16	12.8
>15	20	16.0
Total	125	100.0



In the present study, we observed in 26.9% patients the duration of diabetes was 6 to 10 years. In 41.6 of patients the duration of diabetes was either less than 5 years or upto 5 years. In 16% of patients the duration of diabetes was > 15 years. The mean duration of diabetes was 7.4 ± 5.44 years.

Table - 4. Mode of treatment


Mode of treatment	Distribution (n=125)	
	Number	Percentage
Oral hypoglycemic agents only	70	56
Insulin only	30	24
OHA + Insulin	9	7.2
Newly detected	16	12.8
Total	125	100.0



We observed 70 patients (56%) were on oral hypoglycemic agents, 30 patients (24%) were on insulin preparations, 16 patients(12.8%) were newly detected and 9 patients (7.2%) were on combination of insulin and oral hypoglycemic agents.

Table - 5. Habits


Habits	Distribution (n=125)	
	Number	Percentage
Alcohol only	15	12
Alcohol + smoking	6	4.8
Smoking only	9	7.2
Total	30	24.0



In 15 patients (12%) history of alcohol consumption, 9 patients (7.2%) history of tobacco smoking and in 6 patients (4.8%) history of smoking and alcohol consumption was obtained.

Table - 6. Body mass index (BMI)


Body mass index	Distribution (n=125)	
	Number	Percentage
18.5 to 22.99	2	1.6
23.0 to 24.99	17	13.6
25.0 to 29.99	99	75.6
30 or more	12	9.6
Total	125	100.0



We observed in 94 patients (75.6%) BMI of 25 to 29.99, in 17 patients (13.6%) BMI of 23 to 24.99, in 12 patients (9.6%) BMI was > 30 and in only 2 patients (1.6%) BMI was 18.5 to 22.99. The mean BMI was 26.95 ± 3.15 .

Table - 7. Fasting blood sugar (FBS)


Fasting blood sugar (mg/dL)	Distribution (n=125)	
	Number	Percentage
≤100	2	1.6
101 to 120	2	1.6
121 to 140	25	20
141 to 160	44	35.2
161 to 180	29	23.2
181 to 200	18	14.4
>200	5	4.00
Total	125	100.0



Most of our patients who presented had fasting glucose abnormality (98%) except 4 patients (3.2%).

Table - 8. Post prandial blood sugar (PPBS)


Post prandial blood sugar (mg/dL)	Distribution (n=125)	
	Number	Percentage
≤200	2	1.6
201 to 220	8	6.4
221 to 240	8	6.4
241 to 260	13	10.4
261 to 280	14	11.2
281 to 300	20	16
>300	60	48
Total	125	100.0



Almost all our patients had post-prandial glucose abnormality (98.4%). 2 patients (1.6%) had post-prandial blood sugar <200 mg%.

Table - 9. HbA1c levels


HbA1c (%)	Distribution (n=125)	
	Number	Percentage
6.5 - 7.0	12	9.6
7.1 - 8.0	23	18.4
>8.0	90	72
Total	125	100.0



In our present study 90 patients (72%) had HbA1c of more than 8.0%, 23 patients (18.4%) had HbA1c between 7.1 to 8.0% and only 12 patients (9.6%) were between 6.5 to 7.0%. The mean HbA1c level was 8.26 ± 0.78 .

Table - 10. Fasting lipids - Total cholesterol


Total cholesterol (mg/dL)	Distribution (n=125)	
	Number	Percentage
<200 mg/dL	42	33.6
> 200 mg/dL	83	66.4
Total	125	100.0



42 patients (33.6%) had cholesterol < 200 mg/dL and remaining 83 patients (66.4%) had >200 mg/dL.

Table - 11. Fasting lipids - Low density lipoprotein (LDL)


Low density lipoprotein (mg/dL)	Distribution (n=125)	
	Number	Percentage
<100 mg/dL	64	51.2
> 100 mg/dL	61	48.8
Total	125	100.0



LDL of < 100 mg/dL was observed in 64 patients (51.2%) and in 61 patients (48.8%) >100 mg/dL.

Table - 12. Fasting lipids - High density lipoprotein (HDL)


How density lipoprotein (mg/dL)	Distribution (n=125)	
	Number	Percentage
<40 mg/dL	88	70.4
> 40 mg/dL	37	29.6
Total	125	100.0



In majority of patients (70.4%) HDL was <40 mg/dL, in 37 patients (29.6%) it was > 40 mg/dL.

Table - 13. Fasting lipids - Triglycerides


Triglycerides	Distribution (n=125)	
	Number	Percentage
<150 mg/dL	72	57.6
> 150 mg/dL	53	42.4
Total	125	100.0



In 72 patients (57.6%) Triglycerides were <150 mg/dL, and in remainder 53 patients (42.4%) it was > 150 mg/dL.

Table - 14. Vitamin D level

Vitamin D (ng/ml)	Distribution (n=125)	
	Number	Percentage
Deficiency (<20)	104	83.2
Insufficiency (20 to 30)	11	8.8
Normal (30-100)	10	8.0
Total	125	100.0



We observed in 104 patients (83.2%) the level of Vitamin-D were below normal, in 11 patients (8.8%) the levels were insufficient and in remaining 10 patients (8%) the levels were either normal or more than normal.

Table - 15. Correlation of Vitamin D level with age

Age (years)	Vitamin D							
	<20		≥20 to 30		>30		Total	
	No	%	No	%	No	%	No	%
Upto 50	18	75.0	5	20.83	1	4.16	29	100.00
51 to 60	53	82.5	4	10.00	3	7.50	40	100.00
61 to 70	33	91.66	1	2.77	2	5.55	36	100.00
71 to ≥80	20	80.00	1	4.00	4	6.00	25	100.00
Total	104	83.2	11	8.8	10	8	125	100

p = 0.147

Among 104 patients who had low Vitamin D levels, 53 were in age group of 51-60. Among 11 patients who had insufficient levels of Vitamin D levels, 5 patients were below 50 years of age. Among 10 patients who had normal Vitamin D levels, 4 were in age group 71-80. We obtained a p-value of 0.147 when we correlated Vitamin D levels with age. This p value is insignificant.

Table - 16. Correlation of Vitamin D levels with gender

Age (years)	Vitamin D							
	<20		≥20 to 30		>30		Total	
	No	%	No	%	No	%	No	%
Male	67	87.01	5	6.49	5	6.49	77	100.00
Female	37	77.08	6	12.50	5	10.41	48	100.00
Total	104	83.2	11	8.8	10	8	125	100

p = 0.344

Among 104 patients who had low Vitamin D levels, 67 were males and 37 females. Among 11 patients who had insufficient levels of Vitamin D levels, 5 were males and 6 females. Among 10 patients who had normal Vitamin D levels, 5 were males and 5 females. We obtained a p-value of 0.344 when we correlated Vitamin D levels with gender. This p value is insignificant.

Table - 17. Correlation of Vitamin D level with Duration of diabetes

Duration Diabetes (years)	Vitamin D							
	<20		≥20 to 30		>30		Total	
	No	%	No	%	No	%	No	%
Upto 5	44	84.61	5	9.61	3	5.76	52	100.00
6 to 10	34	91.89	2	5.40	1	2.70	37	100.00
11 to 15	12	75	2	12.5	2	12.5	16	100.00
>15	14	70	2	10.0	4	20.0	20	100.00
Total	104	83.2	11	8.8	10	8	125	100

p = 0.292

Among 104 patients who had low Vitamin D levels, 44 patients had less than 5 years duration of diabetes. Among 11 patients who had insufficient Vitamin D levels, 5 patients had less than 5 years duration of diabetes. Among 10 patients who had normal Vitamin D levels, 4 patients had more than 15 years duration of diabetes. We obtained a p-value of 0.292 when we correlated Vitamin D levels with duration of diabetes. This p value is insignificant.

Table - 18. Correlation of vitamin D levels with body mass Index (BMI)

Body mass Index (years)	Vitamin D							
	<20		≥20 to 30		>30		Total	
	No	%	No	%	No	%	No	%
18.5 to 22.99	2	100.00	0	0.00	0	0.00	2	100.00
23.00 to 24.99	13	76.47	3	17.64	1	5.88	17	100.00
25.00 to 29.99	80	85.00	6	6.38	8	8.51	94	100.00
30 or more	9	75.00	2	16.66	1	8.33	12	100.00
Total	104	83.2	11	8.8	10	8	125	100

p = 0.432

Among 104 patients who had low Vitamin D levels, 80 patients had BMI of 25 to 29.99. Among 11 patients who had insufficient Vitamin D levels, 6 patients had BMI of 25 to 29.99. Among 10 patients who had normal Vitamin D levels, 8 patients had BMI of 25 to 29.99. We obtained a p-value of 0.432 when we correlated Vitamin D levels with BMI. This p value is insignificant.

Table - 19. Correlation of Vitamin D levels with fasting blood sugar

FBS	Vitamin D							
	<20		≥20 to 30		>30		Total	
	No	%	No	%	No	%	No	%
Upto 140	20	68.96	4	13.79	5	17.24	29	100.00
141 to 160	36	81.81	4	9.09	4	9.09	44	100.00
161 to 180	27	93.10	1	3.44	1	3.44	29	100.00
181 to 200	17	94.44	1	5.55	0	0.00	18	100.00
>200	4	80.00	1	20.00	0	0.00	5	100.00
Total	104	83.2	11	8.8	10	8	125	100

p = 0.282

When vitamin D levels were compared with fasting blood sugar most of patients with fasting glucose abnormality had low levels of vitamin D (83.2%) 11 patients (8.8%) had insufficient levels and only 10 patients (8%) had either normal or more than normal levels (p-value = 0.282 is insignificant).

Table - 20. Correlation of Vitamin D levels with post prandial blood sugar

PPBS	Vitamin D							
	<20		≥20 to 30		>30		Total	
	No	%	No	%	No	%	No	%
≤220 to 240	12	66.66	4	15.38	2	11.11	18	100.00
241 to 260	10	76.92	2	15.38	1	7.69	13	100.00
261 to 280	11	78.57	1	7.14	2	14.28	14	100.00
281 to 300	17	85.00	1	5.00	2	10.00	20	100.00
>300	59	90.00	3	5.00	3	5.00	60	100.00
Total	104	83.2	11	8.8	10	8	125	100

p = 0.396

When Vitamin D levels were compared with post prandial blood sugar most of patients with post prandial glucose abnormality had low levels of vitamin-D(83.2%) 11 patients (8.8%) had insufficient levels and 10 patients (8%) had either normal or more than normal levels (p-value=0.396 is insignificant)

Table 21. Correlation of Vitamin D levels with HbA1c

HbA1c (%)	Vitamin D							
	<20		≥20 to 30		>30		Total	
	No	%	No	%	No	%	No	%
6.5 - 7.0	7	58.33	3	25.00	2	16.66	12	100.00
7.1 - 8.0	15	65.21	4	17.39	4	17.39	23	100.00
>8.0	82	91.11	4	4.44	4	4.44	90	100.00
Total	104	83.2	11	8.8	10	8	125	100

p=0.005

When Vitamin D levels were correlated with HbA1c, 104 patients had low levels of Vitamin D (7 patients had HbA1c between 6.5 - 7.0%, in 15 patients HbA1c was 7.1 - 8.0% and in remaining 82 patients HbA1c was > 8.0%)

11 patients had insufficient Vitamin D levels (in 3 patients HbA1c was 6.5 - 7.0% in 4 patients 7.1 - 8.0% and in 4 patients it was >8.0%)

10 patients had normal Vitamin D levels (2 patients had HbA1c between 6.5 - 7.0%, in 4 patients HbA1c was 7.1 - 8.0% and 4 had > 8.0%) We obtained a p-value of 0.005 when we correlated Vitamin D levels with HbA1c. This p value is significant.

Table - 22. Correlation of Vitamin D level with Total cholesterol

Cholesterol (Total)	Vitamin D							
	<20		≥20 to 30		>30		Total	
	No	%	No	%	No	%	No	%
<200	28	66.66	9	21.42	5	11.90	42	100.00
>200	76	91.56	2	2.40	5	6.02	83	100.00
Total	104	83.2	11	8.8	10	8	125	100

p = 0.001

Out 104 patients who had low levels of vitamin D, 28 had < 200 mg% cholesterol level and 76 had > 200 mg%.

11 patients were having insufficient levels of vitamin D. Among them 9 patients had cholesterol of <200 mg % and 2 patients had > 200 mg%.

In 10 patients levels of vitamin D was normal, 5 of them had < 200 mg% cholesterol and 5 had >200 mg% (p-value = 0.001 is significant)

Table-23. Correlation of Vitamin D level with low density lipoprotien

LDL	Vitamin D							
	<20		≥20 to 30		>30		Total	
	No	%	No	%	No	%	No	%
<100	49	76.56	5	7.81	10	15.62	64	100.00
>100	55	90.16	6	9.83	0	0.00	61	100.00
Total	104	83.2	11	8.8	10	8	125	100

p = 0.006

Out 104 patients who had low levels of vitamin D, 49 had < 100 mg% LDL level and 55 had > 100 mg%.

11 patients were having insufficient levels of vitamin D. Among them 5 patients had LDL of <100 mg % and 6 patients had > 100 mg%.

In 10 patients levels of vitamin D was normal, all of them had < 100 mg% LDL (p-value = 0.006 is significant)

Table-24. Correlation of Vitamin-D with high density lipoprotein

HDL	Vitamin D							
	<20		≥20 to 30		>30		Total	
	No	%	No	%	No	%	No	%
<40	72	81.81	8	9.09	8	9.09	88	100.00
>40	32	86.48	3	8.10	2	5.40	37	100.00
Total	104	83.2	11	8.8	10	8	125	100

p = 0.764

Out 104 patients who had low levels of vitamin D, 72 had < 40 mg% HDL level and 32 had > 40 mg%.

11 patients were having insufficient levels of vitamin D. Among them 8 patients had HDL of <40 mg % and 3 patients had > 40 mg%.

In 10 patients levels of vitamin D was normal, 8 of them had < 40 mg% HDL and 2 had >40 mg% (p-value = 0.764 is insignificant)

Table-25. Correlation of Vitamin-D levels with triglycerides

Triglycerides	Vitamin D							
	<20		≥20 to 30		>30		Total	
	No	%	No	%	No	%	No	%
<150	59	81.94	5	6.94	8	11.11	72	100.00
>150	45	84.90	6	11.32	2	3.77	53	100.00
Total	104	83.2	11	8.8	10	8	125	100

p = 0.253

Out 104 patients who had low levels of vitamin D, 59 had < 150 mg% triglyceride level and 45 had > 150 mg%.

11 patients were having insufficient levels of vitamin D. Among them 5 patients had triglyceride of <150 mg % and 6 patients had > 150 mg%.

In 10 patients levels of vitamin D was normal, 8 of them had < 150 mg% triglyceride and 2 had >150 mg% (p-value = 0.253 is insignificant)

DISCUSSION

Management of type 2 diabetes mellitus is a challenge for health care workers, patients and their families. Current management standards focus on optimizing glycaemic control to reduce the risks of long term complications. The main aim of our investigation was to clarify, whether there exists association between vitamin D levels and glycated hemoglobin in patients of type 2 diabetes mellitus

In the present study of 125 patients with type 2 diabetes mellitus, we observed the levels of Vitamin-D and compared it to various factors. In this cross sectional study, we found an inverse association between Vitamin-D levels and HbA1c

In our study, patients age ranged from 39 to 85 years. 61 patients were in the age group of >60 years. 53 patients had low levels of Vitamin-D, 2 had insufficient levels and 6 had either normal or more than normal levels. We observed that levels of Vitamin-D were low with increasing age ($p=0.147$; insignificant). This observation is similar to a study by Baynes KCR et al⁹⁸ ($p<0.05$; significant). May be this finding in their study is because of adjusting various confounding factors and following up of these patients for nearly 30 years. One study by Dalgard C et al⁹⁹ observed low levels of Vitamin-D with increasing age. The reason for this could be the synthesis of Vitamin-D decreases with increasing age due to reduced concentration of 7-dehydrocholesterol in the skin and may be due to reduced absorption of oral Vitamin-D.

Taking gender into consideration, no significant association was found ($p=0.344$; insignificant) in our study. Same observation was made by Ford ES et al.¹⁰⁰

In our study, the duration of diabetes varied from 0 to >15 yrs. We did not find any association between Vitamin-D levels and duration of diabetes. This is in sharp contrast to study by Braun TR et al¹⁰¹ who observed lower Vitamin-D in patients with longer duration of diabetes.

Some of our patients were on treatment either with oral hypoglycaemic agents (56%), insulin preparations (30%) or combination of oral hypoglycemic drugs and insulin (7.2%) and 12.8 % were newly detected diabetics. All of these patients when presented had either fasting blood sugar or post prandial blood sugar abnormality reflecting poor diabetic status. Most of our patients were having low or insufficient levels of Vitamin-D (except 10 patients who had levels either normal or more than normal). Same conclusion was drawn by Braun TR et al.¹⁰¹ This issue needs further evaluation by comparing the diabetic patients with healthy non-diabetic individuals.

We obtained in 24 patients history of alcohol consumption, history of smoking in 20 and 14 patients had history of smoking as well as alcohol consumption. Whether these confounding factors have effects on Vitamin-D levels is not clear. Similar observation was found by Braun TR et al.¹⁰¹ Study by Baynes KCR et al⁹⁸ found no correlation with alcohol consumption or smoking.

When levels of Vitamin-D were compared with BMI, the Vitamin-D levels were less in patients with BMI above 23.0, however, p-value was not statistically significant (p=0.423). In a study by Braun TR et al¹⁰¹ correlation between BMI and low levels of Vitamin-D had significant p-value (p=<0.0001). This difference could be because of small sample size (125 patients) in our study compared to their sample size of 887 patients. In study by Baynes KCR et al⁹⁸ there

was no correlation with BMI.

When Vitamin-D levels were compared with fasting blood sugar, most of patients with fasting glucose abnormality had either low levels of Vitamin-D or insufficient levels ($p=0.280$; insignificant). Braun TR et al¹⁰¹ in their study (sample size 887 cases), observed low levels of Vitamin-D are associated with fasting glucose abnormality ($p=0.022$; significant). Similarly study done by Shanthi B et al¹⁰² (sample size 50 patients) found a negative correlation of Vitamin-D with fasting glucose abnormality ($p=0.534$; insignificant). Study by Lu L et al¹⁰³ and Kotwal SK et al¹⁰⁴ found low levels of Vitamin-D in patients with increasing fasting blood sugars.

When Vitamin-D levels were compared with post prandial blood sugar, almost all our patients with post-prandial blood sugar abnormality had either low or insufficient levels ($p=0.396$; insignificant). Same was observed by Shanthi B et al¹⁰² ($p=0.511$; insignificant).

When correlated with HbA1c the Vitamin-D levels were definitely affected with HbA1c of 6.5% and above. In 10 patients normal levels of Vitamin-D was observed inspite of having HbA1C abnormality, p-value being significant ($p=0.005$). Similar observation was made by Dalgard C et al⁹⁹ ($p=0.01$; significant). In a study done by Lu L et al,¹⁰³ they found an inverse association between Vitamin-D levels and HbA1c, p-value was significant ($p<0.0001$).

An attempt was made to correlate Vitamin-D levels with fasting lipids. We found inverse association between total cholesterol ($p = 0.001$) and low density lipoprotein ($p = 0.006$). There was no association between Vitamin-D levels and triglycerides or high density lipoproteins. One study by Lu L et al¹⁰³ found low levels of high density lipoprotein was associated with low levels of Vitamin-D.

Similar observation was by Ford ES et al.¹⁰⁰

When the available data was analyzed both qualitatively and quantitatively to find out correlation of levels of Vitamin-D in patients of type 2 diabetes mellitus we found a significant correlation when compared with HbA1c, cholesterol and low density lipoprotein (p value being significant). Other variables like age, gender, duration of diabetes, body mass index, fasting blood sugar, post prandial blood sugar, high density lipoprotein and triglycerides when compared, did not show significant correlation.

To overcome this bias with confounding factors and co-morbid conditions, may be large sample size is required. And also comparison of diabetic individuals with non-diabetic healthy individuals is essential to find out the true correlation of Vitamin-D levels with these variables.

SUMMARY

Diabetes and its associated complications are significant public health problems. In our study we found that there was an inverse association between Vitamin D levels and HbA1c in patients with type 2 diabetes mellitus. Lower Vitamin-D levels were associated with poor glycemic control. In addition, we observed a significant correlation of Vitamin-D levels with variable factors like total cholesterol and low density lipoprotein. However, we did not find significant correlation with variable factors like age, gender, duration of diabetes, body mass index, fasting blood sugar, post prandial blood sugar, high density lipoprotein and triglycerides.

Overall, these findings suggest a potential beneficial role of vitamin D in diabetes risk. Confirmation of these findings in future observational studies and, specifically, well-designed randomized controlled trials potentially has significant public health implications given the high prevalence of suboptimal vitamin D status in the general population and the relative ease and low cost at which such an intervention may be implemented.

CONCLUSION

There was an inverse association between Vitamin D levels and HbA1c in patients with type 2 diabetes mellitus. In present study of 125 patients with type 2 diabetes mellitus we found that lower Vitamin-D levels were associated with poor glycemic control. Additionally the levels of Vitamin-D when compared with factors like cholesterol and low density lipoprotein (LDL), we found a significant correlation (p-value being statistically significant).

When correlated with other variables like age, gender, duration of diabetes, body mass index, fasting blood sugar, post prandial blood sugar, high density lipoprotein (LDL) and triglycerides, we found no significant correlation (p-value being statistically insignificant).

Further studies to compare patients with type 2 diabetes mellitus and non-diabetic healthy individuals may be necessary to know the relationship between Vitamin-D levels and other variables.

There is evidence that vitamin D deficiency leads to glucose intolerance and predisposes to type 2 diabetes mellitus. Despite observational studies showing a strong association between Vitamin D deficiency and diabetes mellitus, randomized clinical trials with Vitamin D supplementation are of short duration, with small numbers of patients, and small doses of Vitamin D supplementation, thereby not permitting any definitive conclusions. Questions persist about the optimal level of Vitamin D to prevent the risk of developing diabetes mellitus. However, large long-term clinical trials are needed to clarify these issues. Vitamin D is inexpensive and should a trial confirm its benefit in the prevention of diabetes, it will have a major impact on public health.

BIBLIOGRAPHY

1. Ahmed AM. History of diabetes mellitus. Saudi Med J 2002;23(4):373-378.
2. Fauci AS, Kasper DS, Longo DL, Braunwald E, Hauser SL, Jameson JL, et al. Harrison's principles of internal medicine. United States; McGraw Hill: 2008.
3. Patlak M. New weapons to combat an ancient disease: treating diabetes. FASEB J 2002;16(14):1853.
4. Gupta V, Khadgawat R, Saraswathy KN, Sachdeva MP and Kalla AK. Emergence of TCF7L2 as a Most Promising Gene in Predisposition of Diabetes Type II. Int J Hum Genet 2008;8(1-2):199-215.
5. Permutt MA, Wasson J, Cox N. Genetic Epidemiology of Diabetes. J Clin Invest 2005;115:1431-9.
6. Global burden of diabetes. International Diabetes federation. Diabetic atlas fifth edition 2011, Brussels. Available from: URL: <http://www.idf.org/diabetesatlas>. Access Date: 18.06 2013.
7. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414(6865):782-7.
8. Tripathy BB, Chandalia HB. RSSDI: Textbook of diabetes mellitus. 2nd ed., New Delhi: Jaypee Brothers; 2008.
9. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimate for the year 2000 and projections for 2030. Diabetes Care 2004;127(5):1047-1053.
10. Balhara YPS, Sagar R. Correlates of anxiety and depression among

patients with type 2 diabetes mellitus. *Indian journal of endocrinology and metabolism*; 2012;15(Suppl 1):S50-4.

11. Hollis BW, Wagner CL. Normal serum vitamin D levels. *N Engl J Med* 2005;352(5):515-6
12. Bouillon. Vitamin D: from photosynthesis, metabolism, and action to clinical applicationseds. In: *Endocrinology* DeGroot LJ Jameson JL, eds., Philadelphia, Pa, USA: W. B. Saunders; 2001. p. 1009–28.
13. DeLuca HF. Overview of general physiologic features and functions of vitamin D. *Am J Clin Nutr* 2004;80(6):1689S–96S.
14. Holick MF. Vitamin D deficiency *New Engl J Med* 2007;357:266–81.
15. Sung CC, Liao MT, Lu KC, Wu CC. Role of Vitamin D in Insulin Resistance. *J Biomed Biotechnol* 2012;Article ID 634195: 11 pages.
16. Holick MF. Vitamin D deficiency. *National English J Med* 2007;357(3): 266 281.
17. Vacek JL, Vanga SR, Good M, Lai SM, Lakkireddy D, Howard PA. Vitamin D deficiency and supplementation and relation to cardiovascular health. *Am J Cardiol* 2012;109(3):359-63.
18. Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. *Diabetes Res Clin Pract* 1995;27:181–88.
19. Isaia G, Giorgino R, Adami S. High prevalence of hypovitaminosis D in female type 2 diabetic population (Letter). *Diabetes Care* 2001;24:1496.
20. Seshadria KG, Tamilselvana B, Rajendrana A. Role of Vitamin D in Diabetes. *J Endocrinol Metab* 2011;1(2):47-56.
21. Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a

- review of current trends. *Oman Med J* 2012;27(4):269-73.
22. St Vincent Declaration. Diabetes care and research in Europe. *Diabet Med* 1990;7:360.
 23. The Diabetes Control and Complications Trial (DCCT) research group. The effect of intensive treatment of diabetes on the development of long term complications. *N Engl J Med* 1993;329:977-86.
 24. American Diabetes Association – Clinical Practice Recommendations. *Diabetes care* 2004;27 (suppl 1).
 25. Carpenter MW, Coustan OR. Criteria for screening tests for gestational diabetes. *Am J Obstet Gynecol* 1982;144:768-73.
 26. One adult in ten will have diabetes by 2030. International Diabetes Federation. Available from: URL: <http://www.idf.org/media-events/press-releases/2011/diabetes-atlas-5th-edition>. Access Date 22.06.2013
 27. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004;27(5):1047-53.
 28. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Available at http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed January 5, 2012.
 29. Ahuja MMS. Epidemiological studies in diabetes mellitus in India. In: *Epidemiology of diabetes mellitus in developing countries*. Ahuja MMS (ed), 1979, New Delhi: Interprint.
 30. Ramachandran A, Snehalatha C, Kapur A, Diabetes Epidemiology Study

- Group in India (DESI). High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. *Diabetologia* 2001;44:1094–101.
31. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: *Diabetes Atlas* Gan D, eds. International Diabetes Federation. 3rd ed., Belgium: International Diabetes Federation; 2006. p. 15-103.
 32. Mohan V, Pradeepa R. Epidemiology of diabetes in different regions of India. *Health Administrator* 2009;XXII(1&2):1-18.
 33. Zaman FA, Pal R, Zaman GS, Swati IA, Kayyum A. Glucose indices, frank and undetected diabetes in relation to hypertension and anthropometry in a south Indian rural population. *Indian J Public Health* 2011; 55:34-7.
 34. Vijayakumar G, Arun R, Kutty VR. High prevalence of type 2 diabetes mellitus and other metabolic disorders in rural Central Kerala. *J Assoc Physicians India* 2009;57:563–7.
 35. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D, editor. *Diabetes Atlas*. International Diabetes Federation. 3rd ed. Belgium: International Diabetes Federation; 2006. p. 15-103.
 36. Hales CN, Barker DJ, Clark PM, Cox LJ, Fall C, Osmond C, et al. Fetal infant growth and IGT. *BMJ* 1991;303:1019-22.
 37. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet* 2004;363(9403):157-63.
 38. Wei GS, Coady SA, Goff DC Jr, Brancati FL, Levy D, Selvin E, et al. Blood pressure and the risk of developing diabetes in african Americans and whites: ARIC, CARDIA, and the framingham heart study. *Diabetes*

- Care 2011;34(4):873-9.
39. Dabelea D, Pettitt DJ, Hanson RL, Imperatore G, Bennett PH, Knowler WC. Birth weight, type 2 diabetes, and insulin resistance in Pima Indian children and young adults. *Diabetes Care* 1999;22(6):944-50.
 40. Yarbrough DE, Barrett-Connor E, Kritz-Silverstein D, Wingard DL. Birth weight, adult weight, and girth as predictors of the metabolic syndrome in postmenopausal women: the Rancho Bernardo Study. *Diabetes Care* 1998;21(10):1652-8.
 41. Li Y, Qi Q, Workalemahu T, Hu FB, Qi L. Birth Weight, Genetic Susceptibility, and Adulthood Risk of Type 2 Diabetes. *Diabetes Care* 2012;35(12):2479-84.
 42. Slining MM, Kuzawa CW, Mayer-Davis EJ, Adair LS. Evaluating the indirect effect of infant weight velocity on insulin resistance in young adulthood: a birth cohort study from the Philippines. *Am J Epidemiol* 2011;173(6):640-8.
 43. Wang J, Luben R, Khaw KT, Bingham S, Wareham NJ, Forouhi NG. Dietary energy density predicts the risk of incident type 2 diabetes: the European Prospective Investigation of Cancer (EPIC)-Norfolk Study. *Diabetes Care* 2008;31(11):2120-5.
 44. Hectors TL, Vanparys C, van der Ven K, Martens GA, Jorens PG, Van Gaal LF, et al. Environmental pollutants and type 2 diabetes: a review of mechanisms that can disrupt beta cell function. *Diabetologia* 2011;54(6):1273-90.
 45. Khardori R, Griffing GT. Type 2 diabetes mellitus. Available from: URL: <http://emedicine.medscape.com/article/117853-overview#aw2aab6b2b4>

Access Date: 24.06.2013.

46. Billings LK, Florez JC. The genetics of type 2 diabetes: what have we learned from GWAS? *Ann N Y Acad Sci* 2010;1212:59-77.
47. de Miguel-Yanes JM, Shrader P, Pencina MJ, Fox CS, Manning AK, Grant RW, et al. Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms. *Diabetes Care* 2011;34(1):121-5.
48. Pan A, Lucas M, Sun Q, van Dam RM, Franco OH, Manson JE, et al. Bidirectional association between depression and type 2 diabetes mellitus in women. *Arch Intern Med* 2010;170(21):1884-91.
49. Nouwen A, Winkley K, Twisk J, Lloyd CE, Peyrot M, Ismail K, et al. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. *Diabetologia* 2010;53(12): 2480-6.
50. Siuta MA, Robertson SD, Kocalis H, Saunders C, Gresch PJ, Khatri V, et al. Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behaviors in neuronal retractor null mice. *PLoS Biol* 2010;8(6):e1000393.
51. Feig DS, Shah BR, Lipscombe LL, Wu CF, Ray JG, Lowe J, et al. Preeclampsia as a risk factor for diabetes: a population-based cohort study. *PLoS Med* 2013;10(4):e1001425.
52. Sacks DB. A1C versus glucose testing:a comparison. *Diabetes Care* 2011;34(2):518-23.
53. International Expert Committee International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care* 2009;32:1327-34.

54. American Diabetes Association Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2010;33(Suppl. 1):S62-9.
55. American Association of Clinical Endocrinologists Board of Directors; American College of Endocrinologists Board of Trustees American Association of Clinical Endocrinologists/American College of Endocrinology statement on the use of hemoglobin A1c for the diagnosis of diabetes. *Endocr Pract* 2010;16:155-6.
56. Executive summary. Standards of medical care in diabetes *Diabetes Care* 2011;34:S4-10.
57. Brohall G, Behre CJ, Hulthe J, Wikstrand J, Fagerberg B. Prevalence of diabetes and impaired glucose tolerance in 64-year-old Swedish women:experiences of using repeated oral glucose tolerance tests. *Diabetes Care* 2006;29:363-7.
58. World Health Organization Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. Geneva, World Health Organization, 2006.
59. Aiello LP. Diabetic retinopathy (Technical Review). *Diabetes Care* 1998;21:143-56.
60. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). *BMJ* 1998;317:708-13.
61. Pickup J, Williams G. Text book of Diabetes: Clinical features of diabetic neuropathy. 2nd Ed. Oxford: Black Well Science; 1997.
62. Singer DE, Nathan DM, Anderson KM, Wilson PWF, Evans JC. Association of diabetes with prevalent cardiovascular disease in the

- original cohort of the Framingham Heart Study. *Diabetes* 1992;41:202-8.
63. The Diabetes Control and Complications Trial (DCCT) research group. The effect of intensive treatment of diabetes on the development of long term complications. *N Engl J Med* 1993;329:977-86.
 64. Tuorkey MJ, Abdul-Aziz KK. Strategies for diabetes and pathways of vitamin D. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews* 2010;4(2):101-10.
 65. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. *J Clin Endocrinol Metab* 2007;92(6):2017-29.
 66. Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. *Diabetologia* 2005;48(7):1247-57.
 67. DeLuca HF. Overview of general physiologic features and functions of vitamin D. *Am J Clin Nutr* 2004;80(6 Suppl):1689S-96S.
 68. Norman AW. Minireview: vitamin D receptor: new assignments for an already busy receptor. *Endocrinology* 2006;147(12):5542-8.
 69. Liu E, Meigs JB, Pittas AG, McKeown NM, Economos CD, Booth SL, Jacques PF. Plasma 25-hydroxyvitamin d is associated with markers of the insulin resistant phenotype in nondiabetic adults. *J Nutr* 2009;139(2):329-34.
 70. Milaneschi Y, Shardell M, Corsi AM, Vazzana R, Bandinelli S, Guralnik JM, Ferrucci L. Serum 25-hydroxyvitamin D and depressive symptoms in older women and men. *J Clin Endocrinol Metab* 2010;95(7):3225-33.
 71. de Boer IH, Tinker LF, Connelly S, Curb JD, Howard BV, Kestenbaum B, Larson JC, et al. Calcium plus vitamin D supplementation and the risk

- of incident diabetes in the Women's Health Initiative. *Diabetes Care* 2008;31(4):701-7.
72. Peechakara SV, Pittas AG. Vitamin D as a potential modifier of diabetes risk. *Nat Clin Pract Endocrinol Metab* 2008;4(4):182-3.
73. Kayaniyl S, Vieth R, Retnakaran R, Knight JA, Qi Y, Gerstein HC, Perkins BA, et al. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. *Diabetes Care* 2010;33(6):1379-81.
74. Isaia G, Giorgino R, Adami S. High prevalence of hypovitaminosis D in female type 2 diabetic population. *Diabetes Care* 2001;24(8):1496.
75. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. *Am J Clin Nutr* 2004;79(5):820-5.
76. Zemel MB, Thompson W, Milstead A, Morris K, Campbell P. Calcium and dairy acceleration of weight and fat loss during energy restriction in obese adults. *Obes Res* 2004;12(4):582-90.
77. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. *Diabetes Care* 2007;30(4):980-6.
78. Orwoll E, Riddle M, Prince M. Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus. *Am J Clin Nutr* 1994;59(5):1083-7.
79. Calle C, Maestro B, Garcia-Arencibia M. Genomic actions of 1,25-dihydroxyvitamin D₃ on insulin receptor gene expression, insulin receptor number and insulin activity in the kidney, liver and adipose tissue of

- streptozotocin-induced diabetic rats. *BMC Mol Biol* 2008;9:65.
80. Peeyush KT, Savitha B, Sherin A, Anju TR, Jes P, Paulose CS. Cholinergic, dopaminergic and insulin receptors gene expression in the cerebellum of streptozotocin-induced diabetic rats: functional regulation with Vitamin D3 supplementation. *Pharmacol Biochem Behav* 2010;95(2):216-22.
 81. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. *Prog Biophys Mol Biol* 2006;92(1):39-48.
 82. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, et al. Vitamin D levels and early mortality among incident hemodialysis patients. *Kidney Int* 2007;72(8):1004-13.
 83. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, Quigg RJ, et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. *Kidney Int* 2008;73(2):163-71.
 84. Chonchol M, Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. *Kidney Int* 2007;71(2):134-9.
 85. Calle C, Maestro B, Garcia-Arencibia M. Genomic actions of 1,25-dihydroxyvitamin D3 on insulin receptor gene expression, insulin receptor number and insulin activity in the kidney, liver and adipose tissue of streptozotocin-induced diabetic rats. *BMC Mol Biol* 2008;9:65.
 86. Peeyush KT, Savitha B, Sherin A, Anju TR, Jes P, Paulose CS. Cholinergic, dopaminergic and insulin receptors gene expression in the cerebellum of streptozotocin-induced diabetic rats: functional regulation with Vitamin D3 supplementation. *Pharmacol Biochem Behav*

2010;95(2):216-22.


87. Lee P, Chen R. Vitamin D as an analgesic for patients with type 2 diabetes and neuropathic pain. *Arch Intern Med* 2008;168(7):771-2.
88. Avanell A, Cook JA, MacLennan GS, McPherson GC. Vitamin D supplementation and type 2 diabetes: a substudy of a randomized placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). *Age Ageing* 2009;38(5): 606-9.
89. Renzaho AM, Nowson C, Kaur A, Halliday JA, Fong D, Desilva J. Prevalence of vitamin D insufficiency and risk factors for type 2 diabetes and cardiovascular disease among African migrant and refugee adults in Melbourne: a pilot study. *Asia Pacific Journal of Clinical Nutrition* 2011;20(3):397-403.
90. Shankar A, Sabanayagam C, Kalindini S. Serum 25-hydroxyvitamin d levels and prediabetes among subjects free of diabetes. *Diabetes Care* 2011;34(5):1114-9.
91. Mattila C, Knekt P, Mannisto S, Rissanen H, Laaksonen MA, Montonen J, et al. Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. *Diabetes Care* 2007;30(10):2569-70.
92. Liu E, Meigs JB, Pittas AG, Economos CD, McKeown NM, Booth SL, et al. Predicted 25-hydroxyvitamin D score and incident type 2 diabetes in the Framingham Offspring Study. *Am J Clin Nutr* 2010;91:1627–33.
93. Lindqvist PG, Olsson H, Landin-Olsson M. Are active sun exposure habits related to lowering risk of type 2 diabetes mellitus in women, a prospective cohort study? *Diabetes Res Clin Pract* 2010;90(1):109-14.
94. Grimnes G, Emaus N, Joakimsen RM, Figenschau Y, Jenssen T, Njølstad I,

- et al. Baseline serum 25-hydroxyvitamin D concentrations in the Tromso Study 1994-95 and risk of developing type 2 diabetes mellitus during 11 years of follow up. *Diabetic Medicine* 2010; 27(10):1107-15.
95. Pittas AG, Dawson-Hughes B, Li T, Van Dam RM, Willett WC, Manson JE, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. *Diabetes Care* 2006;29:650–6.
96. ADVIA Centaur Vitamin D Total Assay Specifications. New York, USA: Siemens Healthcare Diagnostics Inc.; 2011. Available from: URL: http://www.medical.siemens.com/siemens/en_GLOBAL/gg_diag_FBAs/files/products_disease_states/bone_metabolism/110781-GC1_Vitamin_D_on_ADVIA_Centaur_SS_Final.pdf Access Date: 21.01.2012.
97. World Health Organisation. The Asia-Pacific perspective: Redefining obesity and its treatment. Australia: International Diabetes Institute Health Communications Australia Pty Ltd; 2000.
98. Baynes KCR, Boucher BJ, Feskens EJ, Kromhout D. Vitamin D, glucose tolerance and insulinaemia in elderly men. *Diabetologia* 1997;40(3):344-7.
99. Dalgård C, Petersen MS, Weihe P, Grandjean P. Vitamin D status in relation to glucose metabolism and type 2 diabetes in septuagenarians. *Diabetes Care* 2011;34(6):1284-8.
100. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. *Diabetes Care*. 2005;28(5):1228-30.
101. Braun TR, Been LF, Blackett PR, Sanghera DK. Vitamin D Deficiency and Cardio-Metabolic Risk in a North Indian Community with Highly Prevalent Type 2 Diabetes. *J Diabetes Metab* 2012;3:100213.

102. Shanthi B, Revathy C, Majuly Devi AJ, Parameshwari PJ, Stephen T. Serum 25(OH)D and type 2 diabetes mellitus. *J Clin Diagnostic Res* 2012;6(5):774-6.
103. Lu L, Yu Z, Pan A, Hu FB, Franco OH, Li H, et al. Plasma 25-hydroxyvitamin D concentration and metabolic syndrome among middle-aged and elderly Chinese individuals. *Diabetes Care* 2009;32(7):1278-83.
104. Kotwal SK, Laway BA, Shah ZA. Pattern of 25 hydroxy vitamin D status in North Indian people with newly detected type 2 diabetes – A prospective case control study.

ANNEXURE - I

ETHICAL CLEARANCE CERTIFICATE



B.L.D.E. UNIVERSITY'S
SHRI.B.M.PATIL MEDICAL COLLEGE, BIJAPUR-586 103
INSTITUTIONAL ETHICAL COMMITTEE

INSTITUTIONAL ETHICAL CLEARANCE CERTIFICATE

The Ethical Committee of this college met on 18-10-2012 at 3-30pm to scrutinize the Synopsis of Postgraduate Students of this college from Ethical Clearance point of view. After scrutiny the following original/corrected & revised version synopsis of the Thesis has been accorded Ethical Clearance.

Title "A study on the association between HbA1C and vitamin D levels in type 2 diabetes Mellitus"

Name of P.G. student Dr. Kamalakar. S. Desai
Medicine

Name of Guide/Co-investigator Dr L.S. Patil
professor of Medicine

DR. TEJASWINI VALLABHA
CHAIRMAN
INSTITUTIONAL ETHICAL COMMITTEE
BLDEU'S, SHRI.B.M.PATIL
MEDICAL COLLEGE, BIJAPUR.

Following documents were placed before E.C. for Scrutinization

- 1) Copy of Synopsis/Research project.
- 2) Copy of informed consent form
- 3) Any other relevant documents.

ANNEXURE – II

CONSENT FORM

A STUDY ON THE ASSOCIATION BETWEEN HbA1C AND VITAMIN D LEVELS IN TYPE 2 DIABETES MELLITUS

Objective and purpose of the study:

This research is intended to estimate the Serum Vitamin D levels in patients with Type 2 Diabetes Mellitus. The principal investigator of the study is Dr. Kamalakar S Desai under the guidance of Dr. L.S.Patil

Procedure:

If you agree to be part of the research study you will be asked the relevant history and will be subjected to relevant clinical examination and investigations. You will also have to give blood sample for the same study.

Risk and Benefits:

The only risk and possible discomfort you might get is while taking blood from your arm for the investigations. It may cause swelling, pain, redness, bruising or infection (rarely happens) at the site from where the blood is drawn.

Alternatives

Taking part in this study is voluntary. You may choose not to take part in this study, or if you decide to take part you can later change your mind and withdraw from the study. Your decision will not change the present or future health care or other services that you receive. The study doctor or sponsorer may stop your participation in this study any time. If you choose not to take part in the study you will receive the standard treatment for patients with your condition.

VOLUNTARY PARTICIPATION/ WITHDRAWAL:

Your participation in this study is entirely voluntary and you may withdraw from the study at any time.

Privacy and Confidentiality

All information collected about you during the course of this study will be kept confidential to the extent permitted by law. The code numbers will identify you in this research record. Information from this study may be published but your identity will be confidential in any publication.

Financial incentives for participation

You will not be paid / offered any gifts /incentives for participating in the study.

Authorization to publish the results

The results of the study would be forwarded to the B L D E University, Bijapur as part of requirement towards the completion of MD degree, review and publishing.

CONSENT FORM

I voluntarily agree to take part in this study by signing on the line below. I may withdraw at any time. I am not giving up any of my legal rights by signing this form. My signature below indicated that I have read this entire consent form or it has been read to me, and has been explained to me in my vernacular language and had all my questions answered. I will be given a copy of this consent form.

Signature /Left Thumb print of the Participant or legally authorized representative.

Participant's Name/ : _____

Signature/ Left Thumb Impression
of the participant's : _____

Name of the legally authorized
representative/ : _____

Guardian Signature/ : _____

Left Thumb Impression. : _____

Witness's Name : _____

Signature/ Left Thumb Impression. : _____

Investigators name and Signature : _____

Date and Place

ANNEXURE - III

PROFORMA

Case No.:

IP number:

Patient Name:

ID number:

Age:

Sex:

Address:

Occupation:

Date of admission:

RESSENTING SYMPTOMS _ _ _ _ _

Classical symptoms of diabetes mellitus (Polyphagia, Polyuria, Polydipsia)	Yes / No
Ischaemic heart disease	Yes / No
Peripheral vascular disease	Yes / No
Cerebrovascular accident	Yes / No
Peripheral neuropathy	Yes / No
Retinopathy	Yes / No
Any other relevant history	Yes / No

HISTORY

Diabetic history

Duration:

Medication:

Hypertension Yes / No

Ischaemic heart disease Yes / No

Cerebrovascular disease Yes / No

Family history Yes / No

Personal history Vegetarian / Mixed

Diet: Yes / No

Smoking: Yes / No

Tobacco chewing: Yes / No

Alcohol: Yes / No

Menstrual history:

General physical examination:

BMI:

Vitals:

Pulse rate:

Blood pressure: Systolic: Diastolic:

Respiratory rate:

Temperature: Febrile / Afebrile

Pallor Yes / No

Icterus: Yes / No

Oedema: Yes / No

Cyanosis: Yes / No

Clubbing: Yes / No

Lymphadenopathy: Yes / No

Systemic examination:

Respiratory system:

Cardiovascular system:

Per abdomen:

Central nervous system:

Fundoscopy

Investigations

Complete blood count

Haemoglobin (gm%):

Total count:

Differential count:

Platelet count:

ESR:

Red blood cell count:

Renal profile

Urea:

Creatinine

Sodium

Potassium

Urine

Routine

Microscopy

Ketone bodies

Blood sugar levels

Fasting:

Post prandial:

HbA1c:

Fasting Serum 25-hydroxy vitamin D:

Lipid profile:

Cholesterol

Low density lipoprotein

High density lipoprotein

Triglycerides

ANNEXURE – IV

MASTER CHART

Y	-	Yes
N	-	No
M	-	Male
F	-	Female
Kg/m ²	-	Kilogram per meter square
YRS	-	Years
PR	-	Pulse rate
BP	-	Blood pressure
RBS	-	Random blood sugar
FBS	-	Fasting blood sugar
PPBS	-	Post prandial blood sugar
ng/ml	-	Nanogram per milliliter
mg/dL	-	Milligram per deci litre
mm Hg	-	Millimeter of mercury
I	-	Insulin
OHA+I	-	Oral hypoglycemic drugs and insulin
OHA	-	Oral hypoglycaemic agents
HTN	-	Hypertension

MASTERCHART

SINO	NAME	IP NO	AGE(YRS)	SEX	DURATION OF DM	ALCOHOL CONSUMPTION	TOBACCO CHEWING	SMOKING	HTN	PR	BP (mmHg)	BMI(kg/m)	RBS	FBS	PPBS	HBA1C	25 HYDROXY VITAMIN D	Total cholesterol	LDL	TG	HDL	TREATMENT	HAEMOGLOBIN	WBC COUNT	PLATELET COUNT (lakhs)	SERUM CREATININR	DIABETIC RETINOPATHY
1	Rudrappa	12968	37	M	0	Y	N	N	N	86	124/82	18.6	104	98	300	7.1	11.06	151	110	158	26	NONE	13.1	7200	2.8	0.8	NO
2	RAJU	14996	42	M	0	N	N	N	N	72	132/86	23	134	100	180	8.1	11.02	152	97	132	37	NONE	10.2	8200	7.9	1.2	NO
3	BHIMAPPA	15597	40	M	0	Y	N	N	N	68	136/78	24.6	150	130	300	8.1	19.26	188	122	168	31	NONE	9.2	3500	2.1	0.7	NO
4	JADHAV	15803	48	M	2	Y	N	N	Y	88	126/90	24.8	148	130	265	8.1	18.03	210	110	172	33	OHA	10.3	5100	8.5	0.7	NO
5	SHIKARSAB	16717	42	M	0	N	N	N	Y	94	146/98	23	152	130	300	8.2	15.16	260	132	184	35	NONE	14.5	6500	5.4	0.9	NO
6	CHIDAMBAR	1995	48	M	4	N	N	N	N	68	124/84	23	156	128	300	8.1	16.21	250	118	180	32	OHA	13	2000	1	1.0	NO
7	BHIMANGOUDA	2620	47	M	3	Y	N	N	N	76	134/78	23.8	160	130	210	8.2	16.52	310	130	168	34	OHA	13.1	4000	2.5	1.5	NO
8	BASAPPA	2824	48	M	15	N	Y	N	Y	88	134/88	30.2	154	182	300	7.8	21.08	276	114	196	24	OHA+I	9.9	9000	3	1.8	NO
9	KASHIM	3036	47	M	0	N	N	N	Y	89	146/9	23.3	142	140	282	9	12.6	270	126	188	34	OHA	13.1	8500	2.7	1.0	NO
10	MADARSAB	3042	73	M	5	Y	N	Y	Y	88	156/96	25.2	146	122	254	7	11.96	260	122	154	33	NONE	10.2	3000	3.7	1.0	NO
11	RAJU	3256	72	M	1	N	N	N	N	76	154/80	25.4	148	140	302	9.4	12.26	220	110	184	28	OHA	11	4900	0.9	1.0	NO
12	RAJESA	3257	72	M	5	Y	y	N	N	68	128/90	23.6	150	116	160	8.1	11.34	210	110	154	36	OHA	9.3	5300	1.7	1.7	NO
13	SAYED	3554	74	M	4	N	N	N	N	78	138/90	26.0	146	130	302	8.8	13.42	269	114	172	36	OHA	10	2500	1.5	1.4	YES
14	SANGAPPA	4284	72	M	1	Y	N	N	Y	86	110/70	25.2	130	132	284	8.8	12.35	202	110	158	26	OHA	14.1	6000	2.1	0.8	NO

SI NO	NAME	IP NO	AGE(YRS)	SEX	DURATION OF DM	ALCOHOL CONSUMPTION	TOBACCO CHEWING	SMOKING	HTN	PR	BP(mmHg)	BMI(kg/m)	RBS	FBS	PPBS	HBA1C	25 HYDROXY VITAMIN D	Total cholesterol	LDL	TG	HDL	TREATMENT	HAEMOGLOBIN	WBC COUNT	PLATELET COUNT (lakhs)	SERUM CREATININR	DIABETIC RETINOPATHY
15	RAMLING	4452	74	M	0	N	N	N	Y	72	100/70	25.2	182	134	202	8.7	15.76	204	112	154	26	NONE	13	6900	3	1.0	NO
16	NEELAMMA	4618	52	F	16	N	N	N	N	68	110/70	27.2	140	162	302	7.8	38.62	206	114	172	26	OHA+I	7	3000	3.1	1.8	NO
17	KADAYYA	4637	53	M	2	Y	N	N	N	88	114/86	25.6	122	124	302	9.1	19.64	208	116	168	27	OHA	13.7	5000	2.7	1.9	NO
18	ASARGALLI	4252	39	M	17	N	N	N	Y	94	116/84	30.2	140	161	206	9.2	22.48	210	118	180	28	OHA+I	10	4200	1.1	1.0	NO
19	GANGAMMA	5322	63	F	17	N	N	N	N	68	118/70	26.23	116	142	302	9.3	38.86	202	120	184	31	OHA+I	11	6000	3.5	1.3	NO
20	MALAPPA	3296	55	M	2	Y	Y	Y	N	76	90/70	30.4	130	122	222	9.4	17.26	204	122	196	34	OHA	12.9	2600	0.8	1.0	NO
21	BHIMASHANKAR	22173	54	M	0	N	N	N	Y	88	116/72	30.6	132	122	302	9.5	17.64	206	124	188	36	NONE	14.1	7000	1.9	1.1	YES
22	SANGANBASAVA	22134	51	M	5	N	N	N	N	88	100/70	30.4	134	124	242	8.6	14.42	208	126	164	28	OHA	13.1	3600	1.2	1.0	NO
23	DANAMMA	3913	81	F	6	N	N	N	Y	89	116/84	25.2	162	146	310	6.5	47.96	210	128	158	26	OHA	8.7	5500	1.4	1.6	NO
24	SIDLINGAPPA	15120	42	M	11	Y	N	N	N	88	120/80	27.4	124	142	330	7.2	29.42	230	113	158	27	I	9.8	6200	2.8	1.8	NO
25	GOPAL	15159	54	M	0	N	N	N	Y	76	114/80	30.6	161	124	296	8.5	17.56	232	114	154	26	NONE	10.5	3100	3.1	1.0	NO
26	SAHADEV	15483	55	M	3	Y	Y	N	N	68	120/80	30.8	142	126	340	8.4	13.28	238	114	172	28	OHA	13.1	5600	2.5	1.0	NO
27	KRISHNAJI	16220	56	M	0	N	N	N	N	86	90/60	30.9	122	148	350	8.9	15.58	237	128	168	30	NONE	7.9	3000	0.7	1.1	NO
28	BABU	16443	54	M	4	Y	Y	N	Y	72	110/70	30.4	122	150	400	7.5	18.76	236	132	180	28	OHA	14	5700	1.9	1.0	NO
29	VITTOBA	16724	58	M	0	N	N	N	N	68	118/70	30.2	146	148	320	8.2	18.34	224	130	182	28	NONE	13.1	2700	2.1	1.1	NO
30	RUSTUM	27 488	44	M	13	N	Y	Y	N	88	124/84	27.6	130	152	290	9.2	27.72	244	116	184	31	I	10.1	6100	3	1.0	NO

SI NO	NAME	IP NO	AGE(YRS)	SEX	DURATION OF DM	ALCOHOL CONSUMPTION	TOBACCO CHEWING	SMOKING	HTN	PR	BP(mmHg)	BMI(kg/m)	RBS	FBS	PPBS	HBA1C	25 HYDROXY VITAMIN D	Total cholesterol	LDL	TG	HDL	TREATMENT	HAEMOGLOBIN	WBC COUNT	PLATELET COUNT (lakhs)	SERUM CREATININR	DIABETIC RETINOPATHY
31	MAHI PATEL	5889	75	M	0	Y	N	Y	Y	94	116/72	30.6	182	156	330	9	11.42	248	120	196	32	NONE	14	5500	2.5	0.9	NO
32	TARACHAND	6281	74	M	3	N	N	N	N	68	132/86	28	140	160	260	7.6	13.96	266	122	198	24	OHA	13.7	3100	1.9	1.1	NO
33	NANAGOWDA	8637	77	M	4	N	Y	N	N	76	126/88	29.2	122	154	360	6.6	15.84	280	128	188	26	OHA	9.1	6900	2.1	0.7	NO
34	BHIMASHANKAR	22173	82	M	2	N	N	N	N	88	100/80	27.8	140	142	282	8.5	13.16	220	112	158	27	OHA	13.9	4100	3.9	1.0	NO
35	SANGANABASAVA	22134	81	M	0	Y	N	N	Y	89	118/86	29.4	116	146	320	8.6	15.24	220	116	154	26	NONE	14	5500	2.7	1.1	NO
36	BHIMASHANKAR	23368	81	M	2	N	Y	Y	N	88	100/70	29.6	130	148	238	8.7	16.66	162	118	172	28	OHA	10.5	6900	1.7	1.2	NO
37	MALLIKARJUN	23318	61	M	3	N	N	N	Y	76	110/80	29.8	132	150	320	8.8	16.48	152	120	168	30	OHA	9.3	4200	0.9	1.1	NO
38	SHEELA DEVI	13877	77	F	18	N	N	N	N	68	108/82	29.5	134	146	293	7.5	65.34	150	112	180	28	OHA+I	16	6000	1.9	0.9	NO
39	SANGAYYA	23989	75	M	4	N	N	N	Y	88	120/84	27.2	162	142	296	8.3	12.02	250	116	182	28	OHA	8.2	4600	2.7	1.0	NO
40	SHIVAJI	24458	65	M	0	N	Y	N	N	76	118/86	25.4	140	150	265	8.3	13.06	172	112	184	31	NONE	14	5500	3.9	0.5	NO
41	SOMAVVA	14376	77	F	16	N	N	N	N	68	122/80	25.6	122	148	254	7.4	42.82	178	116	196	32	OHA+I	12.7	12000	1.9	0.9	NO
42	SIDAPPA	24552	80	M	5	N	Y	N	Y	78	126/84	25.8	140	146	390	8.3	13.54	240	118	198	64	OHA	10.1	3800	1.2	1.1	NO
43	SANGAYYA	24962	51	M	7	N	N	N	N	86	128/86	25.6	116	142	256	6.5	26.36	158	120	188	68	OHA	8	7000	2.1	0.7	NO
44	SHIVANAND	25018	80	M	5	Y	Y	Y	N	72	130/80	25.4	130	146	284	8.8	14.84	150	91	158	42	OHA	13.1	12500	3.1	1.1	NO
45	MAREPPA	30452	80	M	0	N	N	N	N	88	116/82	25.4	132	150	288	8.8	15.36	152	95	154	54	NONE	12	7000	2.9	1.7	NO
46	RAMU	30824	71	M	1	N	N	Y	Y	89	138/86	25.4	134	148	340	8.9	13.48	158	92	172	64	OHA	9.9	5000	2.6	1.0	NO

SI NO	NAME	IP NO	AGE(YRS)	SEX	DURATION OF DM	ALCOHOL CONSUMPTION	TOBACCO CHEWING	SMOKING	HTN	PR	BP(mmHg)	BMI(kg/m)	RBS	FBS	PPBS	HBA1C	25 HYDROXY VITAMIN D	Total cholesterol	LDL	TG	HDL	TREATMENT	HAEMOGLOBIN	WBC COUNT	PLATELET COUNT (laks)	SERUM CREATININR	DIABETIC RETINOPATHY
47	MOHAN	679	52	M	2	N	N	N	N	88	128/84	25.4	162	150	350	9	12.86	162	96	168	68	OHA	13	6000	1.9	1.3	NO
48	MOHAMMED	650	53	M	3	N	Y	N	N	76	132/84	25.2	124	152	238	8.9	11.78	168	88	180	66	OHA	10.1	4100	1.3	0.9	NO
49	GURAPPA	23318	54	M	4	N	N	N	N	68	100/70	25.2	161	154	320	7.2	19.16	172	93	184	68	OHA	14.1	5000	1.9	1.0	NO
50	KUSHINAG	23065	55	M	5	N	Y	N	N	88	126/82	25.6	142	156	258	9	17.68	178	91	196	42	OHA	13.1	2900	1.4	1.0	NO
52	IRANNA	24715	82	M	12	N	N	N	N	89	100/70	25.6	122	128	275	9.2	32.56	168	94	188	24	I	13.1	3100	1.1	1.1	NO
52	SUNDRABAI	30321	56	F	7	N	Y	N	N	88	120/80	25.6	122	158	370	9.3	27.62	182	124	134	48	OHA	10.1	6000	2.3	1.3	NO
53	NAGAPPA	24871	82	M	0	N	N	N	N	76	126/72	25.8	146	160	275	9.4	14.02	188	92	164	50	NONE	13.7	6200	0.8	1.0	NO
54	MUPAYYAIH	24539	81	M	1	Y	N	N	N	68	122/76	25.8	130	152	330	8.2	12.54	182	118	164	42	OHA	11	5000	1.9	0.9	NO
55	RAMACHANDRA	25938	82	M	2	N	Y	N	Y	88	122/84	26	182	154	260	6.6	19.56	188	120	158	52	OHA	13.9	6200	2.1	1.1	NO
56	DEVENDRA	26305	51	M	0	N	N	N	N	89	126/80	26.2	140	156	236	8.2	17.38	192	124	164	62	NONE	13.1	2100	3.9	1.5	NO
57	GURANNA	26575	52	M	6	N	N	N	N	88	110/70	26.4	122	158	350	7.3	14.34	198	126	172	68	OHA	13.1	3200	3.1	1.2	NO
58	BHIMARAYA	27382	53	M	7	Y	Y	N	N	76	116/82	26.6	140	160	360	8.5	12.08	150	130	168	42	OHA	8.8	2400	2.5	1.4	NO
59	MALAPPA	25388	51	M	8	N	N	N	N	68	122/84	26.8	116	158	370	8.6	19.06	192	132	180	52	I	13	1800	3.1	1.5	NO
60	SHIVSHANKRAPPA	321531	52	M	9	N	N	N	N	88	126/82	27	130	152	380	8.7	19.07	152	122	184	62	I	14.1	8000	0.9	1.8	NO
61	DADAGOUD	30273	53	M	10	N	N	N	N	89	126/82	27.8	132	154	236	7.9	16.14	198	124	196	68	I	10.1	4500	3.1	1.1	NO
62	BABUGOUD	3828	55	M	6	N	Y	N	N	88	126/82	26	148	156	390	9	12.76	158	95	188	42	OHA	9.7	3500	2.1	1.0	NO

SI NO	NAME	IP NO	AGE(YRS)	SEX	DURATION OF DM	ALCOHOL CONSUMPTION	TOBACCO CHEWING	SMOKING	HTN	PR	BP(mmHg)	BMI(kg/m)	RBS	FBS	PPBS	HBA1C	25 HYDROXY VITAMIN D	Total cholesterol	LDL	TG	HDL	TREATMENT	HAEMOGLOBIN	WBC COUNT	PLATELET COUNT (laks)	SERUM CREATININR	DIABETIC RETINOPATHY
63	SANGAPPA	4249	56	M	7	N	N	Y	N	76	126/82	26.2	150	158	400	9.1	18.18	162	96	164	52	OHA	13.9	2100	3.9	1.3	NO
64	NINGAPPA	5266	56	M	8	N	Y	N	N	68	126/80	26.4	146	160	252	8.3	15.16	168	97	162	62	OHA	10.2	6000	2.5	1.0	NO
65	CYONSAB	5451	57	M	9	N	N	N	Y	78	124/82	26.6	130	152	296	8.4	13.68	172	94	166	68	OHA	12	1500	0.3	1.1	NO
66	SAVITHRI	24587	59	F	4	N	Y	N	N	86	132/86	25.8	182	136	270	7.8	23.86	258	93	148	42	OHA	8	5100	1.9	1.0	NO
67	MARUTHI	6309	56	M	6	N	N	N	N	72	136/78	25.2	140	142	265	6.7	11.56	150	92	158	40	OHA	9	3000	3.9	1.5	NO
68	MALAPPA	6631	57	M	7	N	N	N	N	86	126/90	25.4	122	146	284	8.8	15.48	152	94	156	42	OHA	14.1	5000	2.9	1.3	NO
69	HANUMANTH	7654	58	M	8	Y	N	N	Y	72	146/98	25.6	140	148	340	8.9	19.26	156	96	164	44	OHA	13.1	1800	4.7	1.9	NO
70	MALAPPA	7562	59	M	9	N	Y	Y	N	68	124/84	25.8	116	176	280	9.4	13.82	158	98	180	46	OHA	8.6	6000	1.9	1.4	NO
71	NANAGOWDA	8329	74	M	14	N	N	N	N	88	134/78	26	130	138	248	7.8	35.64	160	112	184	26	I	13.1	3500	0.9	1.0	NO
72	NAGAPPA	9328	60	M	7	N	Y	N	N	94	134/88	26.2	132	176	290	9.3	16.32	162	88	188	50	OHA	13.7	3000	4.1	1.9	NO
73	JOTHIBA	12502	59	M	5	N	N	N	N	68	146/9	26.4	134	138	270	8.4	40.26	164	120	196	28	OHA	11	2800	4.5	1.9	NO
74	RAMANGOWDA	13082	58	M	8	Y	Y	Y	N	76	156/96	26.8	162	160	380	8.7	12.14	166	92	164	54	OHA	10.1	8000	1.9	1.3	NO
75	RAMANGOWDA	12819	57	M	9	N	N	Y	N	88	154/80	27	124	160	210	7.6	17.76	168	94	128	56	OHA	8.6	5000	0.8	1.9	NO
76	JAFFARALI	13764	56	M	10	N	N	N	N	89	128/90	27.2	138	170	260	8.8	14.08	170	96	130	58	OHA	14.7	5600	3.9	0.9	NO
77	MUTANNA	14815	61	M	8	Y	Y	N	N	88	138/90	26.6	190	161	310	9.2	11.36	172	92	132	60	OHA	8.7	6100	2.8	1.1	NO
78	SRISHAIL	15696	62	M	9	N	N	N	N	76	110/70	26.8	130	162	320	6.5	14.26	174	94	134	62	OHA	9.1	4800	2	2.9	NO

SI NO	NAME	IP NO	AGE(YRS)	SEX	DURATION OF DM	ALCOHOL CONSUMPTION	TOBACCO CHEWING	SMOKING	HTN	PR	BP(mmHg)	BMI(kg/m)	RBS	FBS	PPBS	HBA1C	25 HYDROXY VITAMIN D	Total cholesterol	LDL	TG	HDL	TREATMENT	HAEMOGLOBIN	WBC COUNT	PLATELET COUNT (lakhs)	SERUM CREATININR	DIABETIC RETINOPATHY
79	MAHADEVAPPA	16399	63	M	10	N	N	N	N	68	100/70	26.6	182	163	330	8.7	14.34	176	96	136	64	OHA	10.5	3010	1.1	0.9	NO
80	BASAVARAJ	5804	64	M	6	Y	Y	N	Y	88	110/70	27	184	164	340	8.8	18.46	178	98	138	66	OHA	13.1	6500	2.7	0.9	NO
81	SRIKANTH	7668	65	M	7	N	N	N	N	76	114/86	27.2	186	165	284	8.6	11.86	180	92	124	68	OHA	14	7000	3.1	1.1	NO
82	RAJARAM	7884	66	M	6	Y	N	Y	N	68	116/84	27.4	188	166	380	9.2	13.42	182	93	120	70	OHA	9.1	8000	2.7	1.6	NO
83	SHARADA	5810	67	F	8	N	N	N	N	78	118/70	27.6	190	167	390	7.2	17.82	184	94	130	42	OHA	13.8	2100	2.1	1.4	NO
84	CHANDIBAI	9140	68	F	6	N	Y	N	N	86	90/70	27.8	196	168	400	9	14.38	186	96	134	44	OHA	14.6	5500	3	3.1	NO
85	BILGAVVA	11166	59	F	2	N	N	N	Y	72	116/72	28	192	138	256	6.7	21.86	284	98	144	46	OHA	13.8	4000	2.7	0.7	NO
86	SHANTABAI	11635	70	F	8	N	Y	N	N	86	100/70	28.2	182	169	210	9.3	17.12	188	92	136	45	OHA	10	5100	0.9	0.9	NO
87	NINGAVVA	11814	61	F	9	N	N	N	N	94	116/84	25.2	184	170	260	8.5	14.96	150	92	128	47	OHA	10.1	4100	1.7	0.8	NO
88	ANNAPURNA	12874	62	F	10	N	Y	N	Y	68	120/80	25.6	122	172	310	7.2	18.12	152	94	130	48	OHA	9.8	5500	2	1.0	NO
89	HIRABAI	12838	63	F	8	N	N	N	N	76	114/80	25.8	146	174	320	8.4	13.24	154	96	132	50	OHA	13.7	2000	3.1	0.9	NO
90	PARWATHY	13039	64	F	7	N	N	N	N	88	120/80	25.4	130	176	290	8.5	19.76	156	98	134	52	OHA	13.1	5000	2.5	1.1	NO
91	ANNAVVA	13320	65	F	6	N	N	N	Y	89	90/60	26.6	182	178	270	7.4	16.78	158	92	136	53	OHA	8.7	3100	0.7	0.9	NO
92	PARAMMA	25277	66	F	6	N	Y	N	N	88	110/70	26.8	140	162	350	6.4	17.96	160	94	138	54	OHA	14.1	6000	2.1	1.2	NO
93	MAHADEVI	4670	67	F	8	N	N	N	Y	76	118/70	26.9	122	164	360	8.6	19.34	162	96	124	56	OHA	13.7	5100	0.9	1.8	NO
94	PARWATHY	6604	68	F	9	N	Y	N	N	68	124/84	26.4	140	166	370	8.7	18.34	164	98	120	54	OHA	15	6000	1.9	1.1	NO

SI NO	NAME	IP NO	AGE(YRS)	SEX	DURATION OF DM	ALCOHOL CONSUMPTION	TOBACCO CHEWING	SMOKING	HTN	PR	BP(mmHg)	BMI(kg/m)	RBS	FBS	PPBS	HBA1C	25 HYDROXY VITAMIN D	Total cholesterol	LDL	TG	HDL	TREATMENT	HAEMOGLOBIN	WBC COUNT	PLATELET COUNT (lakhs)	SERUM CREATININR	DIABETIC RETINOPATHY
95	KASHIBAI	6813	69	F	12	N	N	N	N	78	116/72	25.8	116	168	280	8.9	14.16	168	90	130	50	I	13.1	31100	2	1.9	NO
96	SHANKRAMMA	9082	55	F	4	N	Y	N	N	86	132/86	24.8	130	228	238	9.2	21.84	220	92	134	52	OHA	8.9	11000	1.9	1.7	NO
97	BASAMMA	11704	61	F	11	N	N	N	N	72	126/88	27.2	132	166	238	8.2	11.36	170	88	144	54	I	14	6000	3.8	1.1	NO
98	KALAVATHI	12653	62	F	12	N	N	N	N	86	100/80	27.4	148	168	270	8.4	19.48	172	90	136	56	I	11	3800	1.8	1.0	NO
99	NIMBYEVVA	12984	63	F	13	N	Y	N	N	72	118/86	27.6	150	170	380	8.6	18.34	174	92	124	58	I	10.3	12600	0.7	0.9	NO
100	GANGABAI	13637	64	F	14	N	N	N	N	68	100/70	27.8	146	172	252	7.6	17.76	176	94	120	60	I	13.1	2300	2.3	1.3	NO
101	KAMALAVVA	14986	65	F	3	N	N	N	N	88	110/80	23.6	130	138	380	6.8	21.02	178	97	130	62	OHA	9.2	3100	3.7	1.0	NO
102	MUMTAZ BEGUM	15849	67	F	14	N	Y	N	N	94	108/82	28	122	182	290	8.2	13.1	180	95	134	64	I	13.7	6100	0.8	1.0	NO
103	SARASWATI	15990	68	F	13	N	N	N	N	68	120/84	28.2	146	184	360	8.3	17.22	182	97	144	66	I	11	3000	4.5	1.9	NO
104	SHAKUNTALA	609	66	F	12	N	N	N	N	76	124/82	28.4	130	186	270	8.4	16.65	184	93	136	68	I	10.1	8500	1.9	1.3	YES
105	LAKKAVVA	4129	73	F	4	N	N	N	N	88	132/86	23.2	182	130	238	7.8	29.72	186	88	128	70	OHA	9.8	5500	2	1.0	NO
106	GANGABAI	12456	66	F	14	N	Y	N	N	89	136/78	29	140	198	230	8.6	16.84	190	91	130	42	I	13.7	2000	3.1	0.9	NO
107	NANAGOWDA	14101	52	M	2	N	N	Y	N	88	126/90	26.2	122	138	288	9	44.28	150	122	132	44	OHA	13.9	2100	3.9	1.3	NO
108	MALAMMA	15238	64	F	12	N	Y	N	N	76	146/98	26.9	140	190	388	8.8	11.28	152	90	134	46	I	10.2	6000	2.5	1.0	NO
109	SIDRAMAPPA	14590	40	M	4	N	N	Y	N	68	124/84	24.8	116	130	210	6.8	38.28	156	132	136	45	OHA	12	1700	0.3	1.1	NO
110	SONABAI	15790	61	F	12	N	Y	N	N	88	134/78	30.2	130	182	366	7.8	11.16	158	90	138	47	I	9.2	3500	2.1	0.7	NO

SI NO	NAME	IP NO	AGE(YRS)	SEX	DURATION OF DM	ALCOHOL CONSUMPTION	TOBACCO CHEWING	SMOKING	HTN	PR	BP(mmHg)	BMI(kg/m)	RBS	FBS	PPBS	HBA1C	25 HYDROXY VITAMIN D	Total cholesterol	LDL	TG	HDL	TREATMENT	HAEMOGLOBIN	WBC COUNT	PLATELET COUNT (lakhs)	SERUM CREATININR	DIABETIC RETINOPATHY
111	SAROGINI	1069	62	F	11	N	N	N	N	94	134/88	31.2	132	184	294	8.2	19.24	160	92	124	42	I	10.3	5100	8.5	0.7	NO
112	NELAVVA	3068	63	F	16	N	N	N	N	68	146/9	28.2	148	186	356	8.3	12.38	162	88	120	44	OHA+I	14.5	6400	5.4	0.9	YES
113	KAMALABAI	7858	64	F	17	N	N	N	N	76	156/96	26.8	150	188	286	8.4	17.76	164	94	130	46	I	13	2500	1	1.0	NO
114	BHARTHI	12833	65	F	18	N	Y	N	N	88	154/80	28.8	146	190	364	7.3	15.02	166	98	134	48	I	8	4000	2.5	1.5	NO
115	SATYAVVA	14367	66	F	15	N	N	N	N	89	128/90	26.4	130	196	256	8.5	17.64	168	96	144	50	OHA+1	9.9	9500	3	1.0	NO
116	ANNAPURNA	23727	40	F	15	N	Y	N	N	88	138/90	27.6	122	192	324	8.6	13.28	169	98	136	52	OHA+I	12	8500	2.7	1.0	NO
117	MALAMMA	501	39	F	18	N	N	N	N	76	110/70	28.9	146	182	344	7.4	11.28	170	90	124	54	I	10.2	3200	3.7	1.0	NO
118	GIRIJADEVI	603	40	F	15	N	Y	N	N	68	100/70	28.6	130	184	358	8.1	16.24	172	92	120	56	I	11	4900	0.9	1.0	NO
119	SHIVAMMA	2007	41	F	16	N	N	N	N	88	110/70	26.4	182	186	366	8.2	17.84	174	94	130	58	I	9.3	5300	1.7	1.7	NO
120	LAKKAVVA	1995	42	F	15	N	N	N	N	76	114/86	29.8	140	188	372	8.3	12.68	176	98	134	60	I	9.8	5500	2	1.0	NO
121	SUJATHA	5804	43	F	15	N	Y	N	N	68	116/84	30.4	122	190	384	8.4	14.54	178	98	144	62	I	9.2	2000	3	0.9	NO
122	CHANAMMA	23990	45	F	15	N	N	N	N	78	118/70	30.6	140	228	286	6.5	13.82	190	92	136	64	I	10.3	2100	2.7	1.3	YES
123	SHARANAMMA	30673	46	F	20	N	N	N	N	86	90/70	30.8	116	220	294	8.5	19.65	192	94	128	56	I	14.5	6000	3.7	1.0	NO
124	JAYAVVA	22231	47	F	15	N	Y	N	N	72	116/72	30.2	130	226	284	8.6	12.38	194	88	130	58	I	13	1700	0.9	1.1	NO
125	LALITHA	16426	48	F	16	N	N	N	N	86	100/70	30.4	132	228	264	7.6	18.86	198	84	132	60	I	8	3500	1.7	0.7	YES